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ABSTRACT 
Effect of Tulbaghia violacea on the blood pressure and heart rate in male 
spontaneously hypertensive Wistar rats  
I. A. RAJI 
Tulbaghia violacea Harv. (Alliaceae) is a small bulbous herb which belongs to the 
family, Alliaceae, most commonly associated with onions and garlic. In South Africa 
(SA), this herb has been traditionally used in the treatment of various ailments, including 
fever, colds, asthma, paralysis, hypertension (HTN) and stomach problems. The aim of 
this study was to evaluate the effect of methanol leaf extracts (MLE) of T. violacea on the 
blood pressure (BP) and heart rate (HR) in anaesthetized male spontaneously 
hypertensive rats;  and to find out the mechanism(s) by which it acts.  
 
The MLE of T. violacea (5 - 150 mg/kg), angiotensin I (ang I, 3.1 - 100 µg/kg), captopril 
(10 mg/kg), angiotensin II (ang II, 3.1 - 50 µg/kg), losartan (30 mg/kg), phenylephrine 
(0.01 – 0.16 mg/kg), prazosin (1 mg/kg), dobutamine (0.2 – 10.0 µg/kg), propranolol (0.1 
- 12.8 mg/kg), muscarine (0.16 -10 µg/kg), and atropine (0.02 - 20.48 mg/kg) were 
administered intravenously into male spontaneously hypertensive rats (SHR) weighing 
between 300 g and 350 g and aged less than 5 months. The MLE of T. violacea and/or the 
standard drugs were infused alone, simultaneously, or separately into each animal. The 
BP and HR were measured via a pressure transducer connecting the femoral artery and 
the Powerlab. The vehicle (0.2 mls of a mixture of dimethylsulfoxide and normal saline), 
T. violacea (60 mg/kg) and captopril (10 mg/kg) were injected intraperitoneally into 
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some SHR for 21 days to investigate the chronic effect of these agents on plasma levels 
of aldosterone. The mean change, the mean of the individual percentage changes and the 
percentage difference (in mean) observed with each intervention was calculated and 
statistically analyzed using the Student’s t test for significant difference (p < 0.05). The 
Microsoft Excel software was used for statistical analysis. 
 
T. violacea significantly (p < 0.05) reduced the systolic, diastolic, and mean arterial BP; 
and HR dose-dependently. In a dose-dependent manner, ang I, ang II, phenylephrine 
significantly (p < 0.05) increased the BP, while propranolol, muscarine and atropine 
reduced the BP.  The increases in BP due to dobutamine were not dose-dependent. In a 
dose dependent manner, phenylephrine and propranolol reduced the HR, while 
dobutamine increased the HR. The effect of ang I, ang II, muscarine and atropine on HR 
were not dose-dependent; with both increases as well as decreases observed with ang I, 
and II and atropine, while decreases were seen with muscarine. Captopril produced 
significant (p < 0.05) reduction in BP which were not associated with any change in HR. 
The co-infusion of ang I with the MLE produced significant (p < 0.05) reduction in BP, 
which were not associated with significant changes in HR. The co-infusion of ang II with 
the MLE did not produce any significant changes in BP or HR when compared to the 
infusion of the standard drug alone. The co-infusion of phenylephrine with the MLE did 
not produce any significant change in BP or HR when compared to the values obtained 
with the infusion of the standard drug alone, in both the absence and presence of 
prazosin. The co-infusion of dobutamine with T. violacea produced siginificant (p < 0.05) 
increases in DBP which were associated with significant (p < 0.05) reductions in HR, 
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when compared to the values obtained with the infusion of the standard drug alone. The 
co-infusion of atropine with the MLE did not produce any significant change in BP or 
HR when compared to the values obtained with the infusion of atropine alone. However, 
the infusion of T. violacea, 20 minutes after pre-treating animals with atropine (5.12 
mg/kg) lead to dose dependent significant (p < 0.05) increases in BP, which were 
associated with dose-dependent increases in HR. The chronic treatment of animals with 
T. violacea or captropril produced (a) signicant (p < 0.05) reductions in the plasma levels 
of aldosterone when compared to the values obtained in the vehicle-treated group, (b) 
produced signifiant (p < 0.05) reduction in BP in the captopril treated group when 
compared to the vehicle-treated, (c) did not produce any signficant change in BP in the T. 
violacea-treated group when compared to the vehicle-treated group and (d) did not 
produce any signifiant change in HR or body weight in any of the groups. 
 
The result obtained in this study suggests that T. violacea reduced BP and HR in the 
SHR. Secondly, the BP and HR reducing effect of the MLE may involve a) the inhibition 
of the ACE, b) the inhibition of the β1 adrenoceptors, c) the stimulation of the muscarinic 
receptors and d) the reduction of the levels of aldosternone in plasma. The results also 
suggest that the MLE may not act through the angiotensin II receptors or the α1 
adrenergic receptors.  
Key words: Tulbaghia violacea, spontaneously hypertensive rats, blood pressure, heart 
rate, renin angiotensin aldosterone system, angiotensin converting enzyme, angiotensin II 
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receptors, α1 adrenergic receptors,  β1 adrenergic receptors, muscarinic receptors, 
aldosterone. 
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CHAPTER ONE 
INTRODUCTION 
Cardiovascular disease (CVD) is a complex multi-factorial disease (Rahman & Lowe, 2006) 
that accounts for 16.7 million or 29.2% of the total global deaths; with around 80% of deaths 
occuring in middle to low-income countries. At least, 20 million people survive myocardial 
infarction (MI, i.e., heart attack) and stroke each year, many requiring costly clinical care 
(WHO, 2007). In Africa alone, CVD affects 1.3 million people yearly. It however seems that 
stroke rather than ischemic heart disease (IHD), is a unique feature of the health transition 
associated with urbanization of black South Africans (Steyn et al., 2005; Pieters & Vorster, 
2008). Africans (van Rooyen et al., 2002) and African Americans (Hinderliter et al., 2004; 
Suarez et al., 2004) have been observed to respond with heightened vascular reactivity when 
exposed to stress.   
 
Epidemiologic studies indicate that hypertension (HTN), elevated serum lipids, increased 
plasma fibrinogen and coagulation factors, increased platelet activation, alterations in glucose 
metabolism (diabetes mellitus, DM), and smoking are factors positively associated with CVD 
(Wood & Joint European Societies Task, 2001; Seedat, 2007). Sixty per cent of the burden of 
CVD and about 50% of that of coronary heart disease (CHD) globally is caused by HTN 
(Seedat, 2007).  Age (Chalmers, 1999), gender (WHO, 1995), urbanisation (van Rooyen et 
al., 2000), obesity (Stampfer et al., 1991) and certain dietary factors (Appel et al., 1997) 
strongly influence the occurrence of essential HTN. Meanwhile, stroke which is a common 
complication of uncontrolled blood pressure (BP) kills more people than communicable 
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diseases such as acquired immunodeficiency disease syndrome (AIDS) (Ezzati et al., 2002; 
Connor et al., 2005; Mayosi, 2007).  
 
Throughout the ages, man has relied on nature for his basic needs of food, shelter, clothing, 
means of transportation, fertilizers, flavours and fragrances, and, not the least, medicines 
(Gurib-Fakim, 2006). Plants have formed the basis of sophisticated traditional medicine (TM) 
systems that have been in existence for thousands of years and continue to provide mankind 
with new remedies, and WHO estimates that 80% of the population of the world still rely on 
plant-derived medicines for their healthcare (Samuelsson, 2004; Gurib-Fakim, 2006). These 
medicines initially took the form of crude drugs such as tinctures, teas, poultices, powders, 
and other herbal formulations (Balick & Cox, 1997; Samuelsson, 2004).  
 
Natural products and their derivatives represent more than 50% of all the drugs in clinical use 
in the world. Drug discovery from medicinal plants led to the isolation of early drugs such as 
cocaine, codeine, digitoxin, quinine, diosgenin, reserpine, pilocarpine and morphine, of 
which some are still in use (Farnsworth et al., 1985; Newman et al., 2000; Butler, 2004; 
Samuelsson, 2004; Gurib-Fakim, 2006). There has also been a rekindling of interest in 
‘rediscovering natural products’ (Cragg & Newman, 2005) and it seems only 6% of potential 
medicinal plants has been investigated for biological activity and 15% of these for their 
chemical constituents (Gurib-Fakim, 2006).  
 
In contrast to chemical drugs, herbs have sometimes been erroneously claimed to be non-
toxic, due to their natural origin and long-term use as folk medicines (Street et al., 2008). 
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However, problems may arise due to intrinsic toxicity, adulteration, substitution, 
contamination, misidentification, drug-herb interactions, and lack of standardization (Gagnier 
et al., 2006). Both adverse drug reactions and poisonings associated with the use of herbal 
medicines are increasingly being reported; and medicinal plants behave as authentic 
medicines because the chemical substances of which they are formed can have a biological 
activity in humans (Ernst, 2002; Fennell et al., 2004; Zhou et al., 2004; Rodriguez-Fragoso et 
al., 2008). Medicinal plants typically contain mixtures of different chemical compounds that 
may act individually, additively or in synergy to improve health. On the other hand, modern 
medicine usually aims to develop a patentable single compound or a ‘magic bullet’ to treat 
specific conditions (Gurib-Fakim, 2006). Herbal medicines include herbs, herbal materials, 
herbal preparations and finished herbal products which contain as active ingredients parts of 
plants, or other plant materials, or combinations thereof. “Traditional medicine” is often used 
when referring to Africa, Latin America, South-East Asia, and/or the Western Pacific, 
whereas “complementary and alternative medicine” (CAM) is used when referring to Europe 
and/or North America (and Australia) (Wicke, 1995; WHO, 2002; Hanrahan, 2006; Makunga 
et al., 2008). 
 
Africa has a high rate of endemism, and the Southern African region is exceptionally rich in 
plant diversity with some 30,000 species of flowering plants of which 80% are endemic. 
Famous African medicinal plants include Acacia senegal (Gum Arabic), Agathosma betulina 
(Buchu), Aloe ferox (Cape Aloes), Aloe vera (North African Origin), Artemisia afra (African 
wormwood), Aspalanthus linearis (Rooibos tea), Hibiscus sabdariffa (Hibiscus, Roselle), 
Hypoxis hemerocallidea (African potato) and Catharanthus roseus (Rosy Periwinkle) (Good, 
1974; Goldblatt & Manning, 2000; Gurib-Fakim, 2006). As seen in other parts of Africa, it is, 
therefore, not surprising that TM also forms the backbone of rural healthcare in South Africa 
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(McGaw et al., 2005) and an estimated 27 million of the population depend on TMs and 
traditional healers for some or all of their healthcare needs (Cunningham, 1993; Meyer et al., 
1996; Mander, 1998; McGaw et al., 2005). Traditional medicine coexists with modern 
medicine (van Wyk & Gericke, 2000) and caters for the health needs of diverse local 
populations (Mackraj et al., 2008), and is most prevalent in more rural areas where western 
medicines are inaccessible due to unavailability and/or their comparably high cost. The 
sustained high popularity of TM may also be due to it being closely interwoven with the 
cultural and spiritual ideology in South Africa (Hutchings et al., 1996; McGaw et al., 2005; 
Makunga et al., 2008); and more recently, the fact that South Africa has also mirrored the 
paradigm shift towards CAM in developed countries serving a diverse range of consumers 
(Makunga et al., 2008). Plants which have been previously reported to have potential 
beneficial effects against CVD include Allium sativum (garlic), (Dillon et al., 2003; Zahid 
Ashraf et al., 2005), Rauwolfia serpentina (Snake-root) (Gurib-Fakim, 2006), turmeric 
(Deters et al., 2003), Hawthorn (Crataegus laevigata) leaves, flowers and berries (Walker et 
al., 2006) and Tulbaghia violacea (Mackraj et al., 2008; Ramesar et al., 2008). The known 
cardiovascular (CV) effects of these plants will be discussed in more details in the second 
chapter of this thesis. 
 
Tulbaghia violacea (T. violacea) is widely used as herbal remedy for various ailments such as 
fever and colds, asthma, tuberculosis, rheumatism, paralysis, HTN and stomach problems 
(MacDonald et al., 2004; van Wyk & Wink, 2004; Bungu et al., 2006; Bungu et al., 2008). T. 
violacea has been postulated to have similar biological activity as garlic since they belong to 
the same family (Order Asparagales, Family Alliaceae) (van Wyk et al., 1997; van Wyk & 
Gericke, 2000; Bungu et al., 2006; Thamburan et al., 2006).  However, only few publications 
have reported on the biological activities of T. violacea (Jacobsen et al., 1968; Sparg et al., 
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2005; Bungu et al., 2006; Thamburan et al., 2006; Bungu et al., 2008; Naidoo et al., 2008; 
Ramesar et al., 2008; van den Heever et al., 2008; Kirby & Meyers, 2010; Ebrahim & Pool, 
2010). Ramesar et al. (2008) reported that crude leaf extracts of T. violacea inhibited 
angiotensin I converting enzyme (ACE) and also blocked the rise in mean arterial pressure 
(MAP) associated with infusion of exogenous angiotensin I in normotensive male Wistar rats; 
while Mackraj et al (2008) observed a reduction in systemic arterial BP associated with 
decreased renal angiotensin II type 1 (AT1) receptor gene expression in DSS rats.  
 
Pharmacological disruption of the renin angiotensin aldosterone system (RAAS) using ACE 
inhibitors (ACEIs) and angiotensin II (Ang II) receptor blockers offer primary and secondary 
protection to the cardiovascular system (CVS), brain, and kidneys (Nagata et al., 2002). The 
renin angiotensin aldosterone and bradykinin system is a key physiologic regulator of 
vascular tone, salt and water balance, and BP (Gradman, 2009; Lacolley et al., 2009). T. 
violacea has also been reported to have anticoagulant (Bungu et al., 2008), antithrombotic 
(Bungu et al., 2008) and antioxidant (Naidoo et al., 2008) properties. These properties are 
equally beneficial towards the prevention and treatment of HTN and other CVDs. Therefore, 
the motivation for this study is to further elucidate the mechanism(s) by which T. violacea 
may reduce BP in spontaneously hypertensive rats (SHR), and by inference propose 
mechanisms by which the extracts of the plant can help treat HTN in humans. 
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CHAPTER TWO 
LITERATURE REVIEW 
1. PLANTS WITH CARDIOVASCULAR EFFECTS        
1.1.   Allium sativum (Liliaceae) Garlic: Although results obtained from clinical studies 
have been conflicting (Banerjee & Maulik, 2002; Tanamai et al., 2004; Turner et al., 2004), 
the results from in vitro (preclinical) studies and epidemiologic studies indicate that garlic 
may be beneficial against cardiovascular disease (CVD) (Rahman & Lowe, 2006). Garlic and 
its derivatives have been reported to significantly decrease the diastolic BP (DBP) in humans 
(McMahon & Vargas, 1993), decrease both the circulating ang II levels and the systolic BP 
(SBP), while increasing the nitric oxide (NO) system activity in hypertensive rats (Mohamadi 
et al., 2000; Preuss et al., 2001), increase NO production in isolated pulmonary arteries of 
rats (Kim-Park & Ku, 2000), reduce the increases in ACE activity in serum and various 
tissues during the development of HTN in the two-kidney-one-clip (2K1C) hypertensive rats 
(Sharifi et al., 2003), dilate blood vessels (Zahid Ashraf et al., 2005), inhibit angiotensin 
converting enzyme (ACE) (Sendl et al., 1992), possess anti-oxidative properties (Dillon et 
al., 2003); increase fibrinolysis , inhibit blood coagulation, inhibit platelet aggregation and 
thrombus formation (Rahman & Lowe, 2006), reduce lipid levels in blood (Augusti et al., 
2005), possess anti-atherogenic and anti-atherosclerotic effect (Elkayam et al., 2003; 
Kempaiah & Srinivasan, 2005). Undesirable effects have also been reported with the 
consumption of large doses of garlic (Yadav & Verma, 2004).   
1.2. Rauwolfia serpentina (Apocynaceae) (Radix Rauwolfiae): Snake-root is a small 
shrub, with snake shaped woody roots, and is a proven cure for snake bite. R. vomitoria, a 
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related species, contains high amounts of reserpine. A third species, R. canescens is also used 
in West Africa to treat HTN (Gurib-Fakim, 2006).  
1.3. Crataegus monogyna (Hawthorn) and Crataegus laevigata (Hawthorn thorny):  
has been reported to improve cardiac function, reduce afterload, HTN, tachycardia and 
arrhythmia in both clinical and pharmacological studies (Walker et al., 2006).  
1.4. Curcuma longa (Turmeric): and compounds obtained from it have been reported to 
possess vasodilatory (Ashraf et al., 2005); as well as anti-inflammatory, anti-carcinogenic, 
hypolipidemic and antioxidant properties (Deters et al., 2003).  
1.5. Salvia miltiorrhiza (Red sage, Danshen): has been reported to stimulate endothelial 
NO synthase (eNOS) production and reduced BP in the two-kidney, one-clip (2KIC) reno-
vascular HTN
 
model in hamsters (Kim et al., 2007). 
1.6. Other herbs; aside Tulbaghia violacea, with reported CVS protective effect include 
Cissus assamica (Laws.) Craib (Yang et al., 1998), Ocimum gratissimum L. (Labiatae) 
(Lahlou et al., 2004) and Andrographis paniculata (A. paniculata) (Yoopan et al., 2007).  
 
2. TULBAGHIA VIOLACEA 
Tulbaghia violacea Harv. (Alliaceae) is a small bulbous herb. It has attractive mauve or 
purple flowers and hairless leaves arising from a white, fleshy stalk. It belongs to the family, 
Alliaceae, most commonly associated with onions and garlic (figure 2.1); and is commonly 
known as wilde knoffel (Afrikaans), isihaqa (Zulu) or itswele lomlambo (Xhosa). It is also 
called “society garlic”, “sweet garlic” and “wild garlic” based on the assumption that, in spite 
of its garlic-like flavour, its consumption is not accompanied by the development of bad 
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breath as is the case with the real garlic (Allium sativum L). The plant is widespread 
throughout Africa, with the greatest concentration in Southern Africa, and is indigenous to 
Natal, Transvaal and the Eastern Cape region in South Africa where it grows in rocky 
grasslands. In Southern Africa, there are three indigenous genera within this family: 
Agapanthus, Allium, and Tulbaghia. The plant has been used in some cultures as a substitute 
for garlic and chive possibly for culinary and/or medicinal purposes.  It is widely used as 
herbal remedy for various ailments such as fever, colds, asthma, tuberculosis, rheumatism, 
paralysis, HTN, stomach problems and oesophageal cancer; with its leaves and bulbs being 
the parts most commonly used. It is grown around homes to drive away moles and snakes by 
the Zulus of South Africa. Despite its glowing reviews, adverse effects such as 
gastroenteritis, abdominal pain, acute inflammation, sloughing of the intestinal mucosa, 
contraction of the pupils, as well as fatalities have been reported following treatment with 
extracts of the plant. Other related species include, Tulbhagi alliacae which is used to treat 
fever, fits, rheumatism and paralysis and Tulbhagi simmerlerj which is used as a substitute 
for Tulbhagia violacea (van Wyk & Wink, 2004; Bungu et al., 2006; Bungu et al., 2008).  
 
T. violacea has been postulated to have similar secondary metabolites and hence, biological 
activities as garlic since they belong to the same family (Order Asparagales, Family 
Alliaceae) and both have the characteristic sulphur smell of garlic (Bungu et al., 2006). The 
medicinal properties of garlic have been attributed to the sulphur compounds which 
incidentally have been isolated in both plants (Burton & Kaye, 1992; Hirsch et al., 2000; 
Kubec et al., 2002). These sulphur containing compounds are produced when alliinase, an 
enzyme present in all plants belonging to the Allium species, reacts with alliin when the plant 
is bruised/ crushed (Burton & Kaye, 1992; Kubec et al., 2002). The pH optimum of alliinase 
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from both garlic and T. violacea are 6.5; and that for onion 8 (Nock & Mazelis, 1986, 1987). 
Numerous odour forming compounds (Kubec et al., 2002) and bioflavonoids such as 
quercetin (Hutchings et al., 1996) have been isolated from extracts of T. violacea. 
 
Figure 2. 1: Picture of Tulbaghia violacea showing the green hairless leaves and purple 
flowers. The picture was taken by the author of this thesis, i.e., Raji, I. A. 
 
Apart from the cardio-protective properties of T. violacea previously mentioned in  Chapter 1 
of this thesis, the plant has also been reported to have anti-proliferative and pro-apoptotic 
effects in human cancer cell lines (Bungu et al., 2006; Bungu et al., 2008); anti-thrombotic 
activity (Bungu et al., 2008); anti-oxidant properties (Naidoo et al., 2008); anti-fungal 
activity against Candida albicans (Motsei et al., 2003); anti-bacterial activity against 
Staphylococcus aureus and Bacillus subtilis (Gaidamashvili & van Staden, 2002); anti-
helmintic activity (McGaw et al., 2000) and  potential benefits in treating coccidial infections 
(Naidoo et al., 2008). 
                     
3. MODELS IN CARDIOVASCULAR RESEARCH 
The experimental models and preparations used in cardiovascular (CV) research include the 
models that are based on isolated cells or tissues or structures immersed in organ baths 
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(Chorro et al., 2009). Animal models have allowed the study of CVD in the early stages, as 
well as the investigation of the mechanisms of the pathogenesis of CVD and the effects of 
drug intervention in humans (Doggrell & Brown, 1998). Rodent models are most widely used 
due to the possibility for (a) genetic and environmental standardization, (b) availability of a 
broad spectrum of strains tailored to specific scientific problems, and (c) their acceptance by 
the regulatory authorities (Aigner et al., 2010). The use of rats is rational from economic 
viewpoint and many techniques have been developed to measure relevant functional 
parameters. However, there are some drawbacks. For instance, CVDs such as HTN and heart 
failure in humans are usually slowly developing with wide-ranging neurohumoral adaptations 
in contrast to the acute onset of symptoms in many surgical or drug-induced rat models. 
Secondly, CVD is uncommon in young humans but markedly increases with age while most 
models of HTN and heart failure only use young adult rats (Doggrell & Brown, 1998; Chorro 
et al., 2009; Sweeney, 2010). Scientific studies typically begin at “the bench” with basic 
research, before progressing to the clinical level (Takata & Kato, 1996; Y. Suzuki et al., 
2008; Chorro et al., 2009; Y Suzuki et al., 2009). The spontaneously hypertensive rat (SHR) 
and the hereditary obese mice, ob/ob mice, are among the very few excellent animal models 
that excellently mimic the respective human disease, and are therefore, very useful for 
translational research into the common human diseases, HTN and obesity (Nakao et al., 
2009).  
 
The anaesthetized SHR model allows the researcher to record changes in BP and heart rate 
(HR) in intact animals, in response to administered drugs. The rat is anaesthetized with 
sodium pentobarbitone, injected intra-peritoneally, and the trachea is exposed and cannulated 
for artificial respiration. To record changes in HR and BP, the carotid artery, the abdominal 
aorta or the femoral artery is exposed and cannulated. The cannula is connected to a pressure 
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transducer and thence to a suitable instrument to record changes in BP and HR. Drug 
substances are infused via a cannula inserted into either the jugular or femoral vein (Obikeze, 
2009) (figure 2.2). Although there are some drawbacks in using this model, such as the effect 
of anaesthetic agents on BP and HR, and the possible dampening of pressure due to blood 
clotting. The dampening of pressure could be avoided by carefully infusing heparinised 
saline, with care taken to ensure that the volume infused is also removed to avoid volume 
expansion which will also increase the BP. Infusion of excess heparin in the animal must be 
avoided, as it can affect the BP (Hearse & Sutherland, 2000; Kurtz et al., 2005) 
 
Figure 2. 2: The anaesthetized SHR rat model. (a= BP transducer; b= arterial catheter; c= 
venous catheter; d= Oxygen mask; e= syringe pump; f= small animal operating table; g= 
computer running chart 5 software; h= male SHR) (Obikeze, 2009). The above picture was 
adapted from Obikeze (2009), although the methods have been previously used by several 
researchers. 
 
4. THE SPONTANEOUSLY HYPERTENSIVE RAT 
The SHR initially bred in Kyoto, Japan is the most widely studied animal model of essential 
HTN (Doggrell & Brown, 1998; Choi et al., 2009b; Fernandes-Santos et al., 2009; Koprdova 
et al., 2009; Shin et al., 2009; Susic et al., 2009a). The SHR strain was developed by 
Okamoto and Aoki (1963) and has been maintained by selective sibling mating. The 
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normotensive descendants of the Wistar rats, known as the Wistar-Kyoto rats, WKY, 
obtained from the colony in Kyoto from which the SHR strain was derived is often used as 
controls for the SHR (Kurtz & Morris Jr, 1987; Doggrell & Brown, 1998).  
 
Hypertension is present in 100% of SHR. In many colonies, pre-HTN (100 to 120 mmHg) is 
present during the first month of life (Adams et al., 1989; Dickhout & Lee, 1998). Increased 
BP (above 140 mm Hg) is present by 5 weeks of age in many rats, and by 10 weeks of age, it 
is maintained at over 180 mm Hg, frequently exceeding 200 mmHg (Anderson et al., 2006; 
Charles River Laboratories International, 2009). The HR values of the SHR are also usually 
significantly higher than those of the WKY (Valenti et al., 2009). In vivo studies have shown 
that the SHR has an increased cardiac output (CO) with normal total peripheral resistance 
(TPR) in the early stages of HTN, but as the animal progresses into the established HTN 
state, the CO returns to normal while the hypertrophied blood vessels produce an increase in 
the TPR (Smith & Hutchins, 1979). The SHR also develops left ventricular hypertrophy 
(LVH), increased BP and BP variability; all of which are important indices of heart damage 
(Zamo et al., 2010). An advantage of the SHR is that compounds which lower BP in this 
strain also lower BP in hypertensive humans. A criticism of the SHR model is that little is 
known about the cause of the onset of HTN, although it has been around for a long time 
(Doggrell & Brown, 1998).  
 
Other strains of rats used in CV research, aside the SHR and WKY; include the New Zealand 
genetically hypertensive rats (GH); the Dahl salt sensitive (DSS) and Dahl salt-resistant 
(DSR) rats; the Obese SHR (Koletsky); the SHR-stroke prone (SPSHR); the Israel 
deoxycorticosterone acetate (DOCA) salt-sensitive (SBH) and Israel DOCA salt-resistant 
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(SBN) rats; the Lyon hypertensive (LH), Lyon normotensive (LN) and Lyon low BP (LL) 
rats (Doggrell & Brown, 1998; Anderson et al., 2006; Charles River Laboratories 
International, 2009).  
 
5. THE AUTONOMIC NERVOUS SYSTEM 
The autonomic nervous system (ANS) plays a vital role in the control of the CV activity, 
therefore, impairment of its activity will lead to a corresponding disruption in its function 
(McCorry, 2007; Scigliano et al., 2008; Thayer et al., 2010). The ANS has two major 
branches, i.e., the sympathetic system (SNS) and the parasympathetic systems (PNS). The 
SNS enables the body to respond to challenges to survival, situations of haemodynamic 
collapse or respiratory failure; and its responses include increases in HR, BP, and CO and a 
decline in metabolic activity.  Meanwhile, the PNS regulates the conservation and restoration 
of energy by causing a reduction in HR and BP; and facilitating the digestion and absorption 
of nutrients and the discharge of wastes. The activities of the two systems are normally in a 
dynamic balance (Thayer et al., 2010). Interestingly, a large proportion of patients with HTN 
have increased sympathetic activity, associated with decreased parasympathetic activity 
(Dauphinot et al., 2010; Joyner et al., 2010). 
 
6. THE CARDIOVASCULAR SYSTEM 
The cardio-vascular system (CVS) generally consists of the heart (cardio) and blood vessels 
(vascular). Specifically, the CVS can be viewed as the pulmonary circulation and the 
systemic circulation. The two circulations are arranged in series and, the right and left heart 
chambers must pump identical volumetric flow rate in health. The primary function of the 
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CVS is to circulate the blood through the capillaries to within diffusion distances (less than or 
equal to 10 μm) of every tissue parenchyma. Blood serves as the vehicle for delivery and 
removal of nutrients and waste products respectively, while the vessels serve as the 
highways. These ‘highways’ have a passive capacitance function that maintains the BP in 
diastole, and an active auto-regulatory control that allows the organ to respond to local 
metabolic demands (Kassab, 2006). 
 
6.1. THE VASCULAR SMOOTH MUSCLE CELLS  
The vascular
 
smooth muscle (VSM) cells (VSMCs) are the major cellular component of the 
vascular media and mediate vasodilatation and vasoconstriction. They are innervated by 
sympathetic and parasympathetic fibres and depend on the vasa vasorum located in the outer 
layer of the vessel wall which sends branches into the outer part of the media for oxygen and 
nutrients. Numerous hormones and growth factors act on the VSMCs to cause migration, 
proliferation, and the secretion of extracellular matrix (Günthner et al., 2009). Rapid changes 
in vascular diameter primarily depend on the contractile
 
activation and interaction of actin 
with myosin in VSMCs (Martinez-Lemus et al., 2009). 
 
6.2. THE ENDOTHELIUM 
The human vascular endothelium constitutes approximately 1% of the total body mass (1 kg) 
and has a surface area of approximately 5000 m
2
. The endothelium is a multifunctional 
endocrine organ strategically placed between the vessel wall and the circulating blood, and 
has a key role in vascular homeostasis. The endothelium is both a target for and a mediator of 
CVDs such as HTN, diabetes, insulin resistance, obesity and hyperlipidaemia (Galley & 
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Webster, 2004; Khazaei et al., 2008; Günthner et al., 2009; Higashi et al., 2009; Huang, 
2009). Through
 
flow-mediated release of vaso-active autacoids, endothelial cells are
 
important participants in scenarios leading to remodelling of
 
resistance vessel structure. 
Ultimately, the endothelium with
 
neural, hormonal, and metabolic stimuli, collectively 
influence
 
VSM function and the structure of the vessel
 
wall (Günthner et al., 2009; Martinez-
Lemus et al., 2009). The normal functions of the endothelium include mediating 
vasodilatation (Vanhoutte, 2009), haemostasis (Gross & Aird, 2000), angiogenesis (Lingen, 
2001; Szekanecz & Koch, 2001), inflammation and immune response (Khazaei et al., 2008), 
and also acting as a “tissue-blood barrier” (Irie & Tavassoli, 1991; Toborek & Kaiser, 1999).  
The endothelium generates relaxing factors such as; the endothelium-derived relaxing factor 
(EDRF/NO) (Vanhoutte, 2003; Forstermann & Munzel, 2006); b) prostacyclin (Coleman et 
al., 1994); endothelium-derived hyperpolarizing factor (EDHF) (Emerson & Segal, 2001; 
Ellis & Triggle, 2003). It also generates contracting factors; such as endothelin-1 (Shah, 
2007); thromboxane
 
A2, prostaglandin endoperoxide (Stankevicius et al., 2003) and 20-
hydroxyeicosatetraenoic acid (20-HETE) (McGiff & Quilley, 2001).  
 
6.2.1. ENDOTHELIUM DYSFUNCTION 
Endothelial dysfunction occurs when the endothelial cells do not carry out their normal 
physiologic and protective functions. This leads to progressive degeneration of the CVS, 
characterized by a decline in NO synthase (NOS) activity. There is also an exaggerated 
increase in the release of paracrine factors, which act either as growth factors to induce 
VSMC proliferation or as chemokines to recruit circulating inflammatory cells (Channick et 
al., 2004; Deanfield et al., 2007; Khazaei et al., 2008; Günthner et al., 2009).  
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6.3. THE CONTROL OF BLOOD VESSELS 
The vascular tone (the active tension of smooth muscles in the tunica media) controls the 
width of blood vessels. This tone regulates local blood flow, arterial pressure, capillary 
filtration and central venous pressure; and is under the influence of intrinsic and extrinsic 
factors. The intrinsic factors include the a) myogenic response (arterial vessels contract when 
BP rises), b) endothelial secretions (NO, EDHF, prostacyclin, endothelin-1), c) vasoactive 
metabolites (adenosine, carbon (IV) oxide, oxygen, lactate, potassium ions), d) autacoids 
(histamine, bradykinin, serotonin, prostaglandins, thromboxane A2), e) local pH and f) 
temperature. Meanwhile the external influences include the a) vasomotor nerves involved in 
short term regulation; and b) circulating hormones (such as adrenaline, noradrenaline, 
vasopressin, angiotensin II, histamine) involved in long term regulation (Levick, 2003; 
Ganong, 2005; Pocock & Richards, 2006).  
 
6.4. THE ARTERIAL BLOOD PRESSURE 
The pressure in the aorta and in the brachial and other large arteries in a young adult human 
rises to a peak value (systolic pressure, SBP) of about 120 mm Hg during each heart cycle 
and falls to a minimum value (diastolic pressure, DBP) of about 70 mm Hg (Joyner et al., 
2008). The SBP reflects how much the energy of ejection is able to compress the arterial 
contents downstream of the ventricles. The combination of the stroke volume (SV) and SBP 
in normal individuals can be used to assess cardiac workload, most commonly calculated by 
the product of HR and SBP, and termed rate-pressure product. The DBP is influenced by the 
period over which the pressure can fall, so the HR in itself is a major determinant of DBP, 
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with tachycardia predictably causing a pressure rise. A second major determinant of DBP is 
the speed at which the pressurized blood flows out through the resistance of peripheral blood 
vessels. Therefore, the TPR is also a major determinant of DBP (Bell, 2008). The pulse 
pressure (PP) is the difference between the SBP and DBP (Ganong, 2005). The mean arterial 
pressure (MAP) is the average pressure throughout the cardiac cycle, and its approximate 
value is obtained from the DBP plus one third of the PP (Ganong, 2005; Bell, 2008; Joyner et 
al., 2008). 
 
6.5. THE PERIPHERAL VASCULAR RESISTANCE 
The peripheral resistance is determined mainly by the diameter of the lumen of resistant 
arterioles, and to a lesser extent, that of the medium and large arteries. Luminal diameter can 
be altered actively by the contraction of smooth muscles, or passively by remodelling; under 
the influences of the hemodynamic load, neuro-humoral regulation and the concentrations of 
sodium and potassium ions (Hulin et al., 2009). The product of the TPR and CO gives the 
arterial BP (Levick, 2003). 
 
6.6. BARORECEPTORS   
These are stretch receptors in the walls of the heart and blood vessels that monitor blood 
flow. They are the input end of the arterial baroreflex and are located in the carotid sinus and 
the aortic arch. Afferent signals are sent via the glosso-pharyngeal and vagus nerves to the 
vasomotor centre (VMC) (of the nucleus tractus solitariis) in the medulla oblongata. Efferents 
from the VMC are inhibitory to the tonic discharge of vasoconstrictor nerves; and excitatory 
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to the vagal innervations of the heart leading to vasodilation, venodilation, hypotension, 
bradycardia and fall in CO (Ganong, 2005).  
 
The ultimate goal of the arterial baroreflex is to maintain arterial BP homeostasis. The 
baroreceptors chronically reset to a higher “set point” when arterial BP is chronically 
elevated; and defends the higher BP, until the set point is again adjusted (Brunner et al., 
1979; Ganong, 2005; Bogachev et al., 2009). Baroreceptor sensitivity is impaired in many 
experimental models of HTN, and appears to precede the onset of HTN (Peach, 1977). 
Impaired baroreflex is believed to lead to significant dysregulation of BP; leading to 
increased BP variability, orthostatic hypotension, aberrant pressure rises with major risk of 
fatal events such as myocardial infarction (MI) and stroke (Tozawa et al., 1999; Mancia & 
Parati, 2003; Di Rienzo et al., 2009); and has been reported in several models of HTN such as 
SHR, 2KIC hypertensive model and Lyon hypertensive rat. Angiotensin II inhibits 
baroreceptor function (Huang & Leenen, 1998; Huang et al., 2006; Xie et al., 2006; Parsons 
& Coffman, 2007; Carlson & Wyss, 2008; Cravo et al., 2009). 
 
6.7. CARDIAC OUTPUT (CO) 
The volume of blood pumped out of each ventricle per minute = 5 litres/min in humans. It is 
influenced by venous return, HR, and cardiac contractility (Levick, 2003; Ganong, 2005; 
Pocock & Richards, 2006). 
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6.8. HEART RATE 
This is the number of times the heart beats/contracts in a minute. Heart rate (HR) and stroke 
volume are the main factors used by animals to effectively adapt CO to metabolic demands 
(Levine, 1997); and in normal adults, it depends on the pacemaker activity of the sinoatrial 
(SA) node cells and constantly varies under the influence of a number of non-modifiable and 
modifiable factors (Valentini & Parati, 2009). The non-modifiable factors include age 
(Yamaguchi et al., 2005) and sex (with women generally having higher resting HR when 
compared with men) (Stolarz et al., 2003). The modifiable (physiologic) factors include (i) 
circadian rhythm (HR is usually lower during sleep) (Ben-Dov et al., 2007); (ii) BP (HR is 
positively associated with BP) (Zhang & Kesteloot, 1999); (iii) physical activity  (training 
reduces the resting HR (Borresen & Lambert, 2008); (iv) mental stress (increases 
catecholamines, and hence HR and BP) (Carter & Ray, 2009); (v) smoking (increases HR and 
BP) (Groppelli et al., 1992); (vi) alcohol consumption (increases HR) (Kloner & Rezkalla, 
2007) and (vii) excess body weight, (increases HR) (S. Julius et al., 2000). The importance of 
the resting HR as a prognostic factor and potential therapeutic target is not yet generally 
accepted, even though recent large epidemiologic studies have confirmed earlier studies that 
showed resting HR to be an independent predictor of CV and all-cause mortality in men and 
women with and without diagnosed CVD. Studies have also found a continuous increase in 
CV risk with HR above 60 beat per min (bpm) (S Julius, 2009; Perret-Guillaume et al., 2009; 
S Julius et al., 2010). Among mammals, with the exception of the human species who has on 
the basis of his resting HR doubled his life time, there is a linear, inverse semi-logarithmic 
relation between HR and life expectancy (Levine, 1997). 
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6.8.1. HEART RATE VARIABILITY 
Heart rate variability (HRV) is a non-invasive, practical and reproducible measure of the 
function of the ANS. A HR that is variable and responsive to demands is believed to bestow a 
survival advantage, whereas reduced HRV may be associated with poorer CV health and 
outcomes (Nunan et al., 2010; Routledge et al., 2010; Thayer et al., 2010; Wheat & Larkin, 
2010).  
 
6.9. ACID- BASE BALANCE AND HAEMODYNAMICS 
Although, the normal range of pH for clinical laboratories is 7.35-7.45, in vivo pH is 
maintained within a much narrower range. Blood pH varies in response to respiratory or renal 
impairment. A reduction in the peri-vascular pH decreases the responsiveness to 
vasoconstrictors and consequently, leads to difficulty in maintaining systemic BP (Wagner et 
al., 2009).  
 
7. HYPERTENSION 
Hypertension (HTN) is a sustained elevation of the systemic arterial BP (Ganong, 2005). It 
can either be (a) essential HTN or (b) secondary HTN.  Essential HTN is the HTN without 
any obvious predisposing organic cause (Levick, 2003). Approximately 93% of all HTN are 
of the essential type (Williams, 2008). Secondary HTN has identifiable pathological cause 
such as (a) hyperaldosteronism (b) renal artery stenosis, (c) phaeochromocytoma, (d) pre-
eclamptic toxaemia (Levick, 2003). Sadly, HTN in childhood has now been recognized as a 
common and serious problem, with a prevalence of between 2% to 5% (Kavey et al., 2010).  
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In humans, a daytime BP of less than 120/80 mm Hg is regarded as optimal, while BP less 
than 130/85 mm Hg is regarded as normal. Repeated measurements of resting BP above 
140/90 mm Hg in humans under 50 years old, or 160/95 mm Hg in an older individual is 
considered to be HTN (Williams, 2008; Hulin et al., 2009).  In rats, BP below 125/83 mm Hg 
is considered to be normal, while a SBP above 140 mm Hg is generally considered to be 
HTN (Anderson et al., 2006; Charles River Laboratories International, 2009).  
 
8. CONTROL OF HIGH BLOOD PRESSURE 
Blood pressure is regulated by the CV, renal, endocrine, and central nervous systems and it in 
turn controls these systems via negative feedback mechanisms. Chronic rise in BP leads to 
vascular remodelling with resultant thickening and sclerosis of vessel walls, consequent 
endothelial dysfunction, loss of NO production, and irreversible rise in TPR (Aggarwal & 
Khan, 2006; Chang & Hollander, 2008). The failure to control high BP is multi-factorial in 
most patients, but usually includes lack of disease awareness, lack of consensus among 
treatment guidelines, diet and lifestyle factors, poor patient adherence to dietary/lifestyle 
initiatives and prescribed drug regimens (Sever et al., 2009). Irrespective of the level of HTN, 
lowering of BP is always preferable by non-pharmacological means such as adequate sleep, 
low salt diet, weight loss, exercise and alcohol restriction (Williams, 2008; Kones, 2011).  
 
9. PHARMACOLOGIC INTERVENTION 
This can be done by (a) disrupting the RAAS, (b) reducing TPR, (c) reducing the CO and (d) 
reducing the extracellular fluid (ECF) volume (Levick, 2003; Hoffman, 2011).  
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9.1. THE RENIN ANGIOTENSIN, ALDOSTERONE AND BRADYKININ 
SYSTEM (RAABS) 
The RAABS/RAAS is a key physiologic regulator of vascular tone, salt and water balance, 
BP, bradykinin system and pituitary gland hormones (Gradman, 2009; Lacolley et al., 2009; 
Zamo et al., 2010). Short term activation of the system is geared towards maintaining 
intravascular volume, BP, and tissue repair; however, chronic activation leads to chronic 
vasoconstriction and elevation of BP, VSMC growth/migration, endothelial dysfunction, 
oxidative stress, the release of cytokines and inflammatory cell activation, fibrosis, and 
thrombosis. All these will lead to vascular and myocardial hypertrophy, left ventricular 
remodelling, atherosclerosis, and glomerulosclerosis. The resultant structural changes can 
ultimately result in MI, stroke, and end-stage renal disease. Based on the pivotal role the 
system plays in the development and progression of HTN and HTN- related end organ 
damage, deactivation of the system is crucial in treating HTN and related end organ damage 
(Gradman, 2009). 
 
9.1.1. PRO-RENIN AND RENIN 
The synthesis of ang I and ang II is impossible in the absence of renin (or pro-renin) (figure 
2.3). Renin cleaves the decapeptide ang I from the amino terminus of angiotensinogen (Fisher 
& Hollenberg, 2001). Renin is produced through the activation of pro-renin. Pro-renin is 
synthesized as a pre-prohormone (Gradman & Kad, 2008). Renin secretion is mainly 
regulated by the pressure in the afferent arteriole of the kidney, sympathetic nerve stimulation 
of the β1 adrenergic receptors in the juxta-glomerular apparatus (JGA), sodium ions (Na
+
) at 
the macula densa and negative feedback by Ang II (Brown, 2006).  
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Prorenin, initially believed to be inactive, becomes enzymatically active when bound to the 
(pro) renin receptors (localized to the VSMCs; human heart, kidney, and brain; mesangial 
cells; and cells in the distal and collecting tubules of the renal parenchyma) and can also 
produce ang I. This pathophysiologic role seen in vascular and renal disease is a clinical 
index of small vessel disease in patients with diabetes. Prorenin binds with greater affinity to 
this receptor than renin and the rate of ang I production is increased by 4 to 5 times with 
receptor-bound renin when compared to free renin (Nguyen et al., 2002; Gradman & Kad, 
2008; Gradman, 2009). Aliskiren is a potent orally active competitive inhibitor of renin in 
animals and humans and binds directly unto renin (Gradman & Kad, 2008; Riccioni et al., 
2010). 
 
Figure 2. 3: Schematics illustrating the involvement of ACE and ACE 2 in the regulation of 
the functions of the RAAS (A), and the kinin-kininogen system (B), carboxypeptidase A, CPA 
(Lambert et al., 2008). 
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9.1.2. ANGIOTENSIN-I CONVERTING ENZYME (ACE) 
Angiontensin I (ang I) is rapidly converted to ang II by the ACE located on endothelial cells 
in vascular beds and on the membranes of many other cells including the brush border 
membranes of the renal proximal tubules (Mezzano et al., 2003). The ACE cleaves the C-
terminal dipeptide from Ang I and bradykinin, i.e., it interacts with both the RAAS and the 
kallikrein–kinin system (Hanif et al., 2010). Approximately, 10% of ACE circulates in the 
plasma, while the rest is found in the tissues, heart, brain, kidney, and arteries. The 
circulating RAAS that controls acute hemodynamic modulation is an ACE-dependent system. 
 
Angiotensin II acts on both the ang II type 1 (AT1) and the angtiotensin II type 2 (AT2) 
receptors (figure 2.3) (Gradman, 2009). The ACE 2 shares 42% identity with the catalytic 
domain of ACE (Towler et al., 2004) and is able to metabolize ang I into the nonapeptide 
Ang-(1–9). Ang II itself is also a substrate for ACE 2, and is the preferred pathway for ACE 2 
with an almost 500- fold greater efficiency than the cleavage of ang I. (figure 2.3) (Luhder et 
al., 2009). 
 
Inhibitors of ACE (ACE-Is) arose from early studies performed in the 1960s showing that 
components of venom from the Brazilian arrowhead viper (Bothrops jararaca) inhibited 
kinase II, an enzyme involved in the degradation of bradykinin and later found to be identical 
to ACE.  Analogues of the nonpeptide fraction of the snake venom (teprotide) which 
inhibited ACE were found to lower BP in hypertensive patients and produce beneficial 
effects in heart failure patients. Subsequent research revealed that ACE inhibition could be 
achieved by succinyl amino acids (e.g., carboxyalkanoyl and mercaptoalkanoyl derivatives), 
a finding which ultimately led to the discovery of captopril. Since that time, a plethora of 
ACE-Is having been developed (enalapril, quinapril, ramipril, spirapril, e.t.c.) which share a 
 
 
 
 
25 
 
common structural moiety that interacts with the zinc ion in the ACE active site. Initially 
introduced as antihypertensive agents, ACE-Is have demonstrated clinical efficacy in the 
treatment of a wide range of CV and renal diseases, including heart failure, MI, chronic renal 
failure, and sclerodermal renal crisis (De Leo et al., 2009; Bakris, 2010; Hanif et al., 2010). 
These agents also inhibit the enzyme kininase II which catalyzes the breakdown of 
bradykinin and related peptides; therefore the reduction in BP is a result of both a decrease in 
the levels of ang II as well as an increase in the levels of bradykinin. They also stimulate 
whole body glucose dispersal and uptake of glucose by skeletal muscle by increasing insulin 
sensitivity and upregulation of the cell surface glucose transport protein glucose transporter, 
(GLUT)–4, in insulin resistance states. However, ang II can be formed via non-ACE 
dependent pathways, that are not affected by ACE inhibitors; hence, circulating 
concentrations can return to normal in some patients, despite continuing treatment (a 
phenomenon known as “angiotensin escape”) (Unger & Stoppelhaar, 2007). 
 
9.1.3. ANGIOTENSIN II  
Angiotensin II (ang II) is the most powerful biologically active product of the RAAS (figures 
2.3.). The ACE removes the carboxy-terminal dipeptide of ang I to produce the octapeptide 
ang II (Toda et al., 2007; Skrbic & Igic, 2009). Angiotensin II directly constricts VSMCs, 
enhances myocardial contractility, stimulates aldosterone production, blunts the baroreflex, 
stimulates the release of catecholamines from the adrenal medulla and sympathetic nerve 
endings, increases sympathetic nervous system activity, and stimulates thirst and salt appetite. 
Locally produced ang II induces inflammation, cell growth, mitogenesis, apoptosis, 
migration, and differentiation, regulates the gene expression of bioactive substances, and 
activates multiple intracellular signalling pathways (Kobori et al., 2007; Carlson & Wyss, 
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2008). Angiotensin II also plays an important role in atherosclerosis. Most of its 
hypertensinogenic actions are mediated through the AT1 receptor; even though an angiotensin 
II type 2 (AT2) receptor, has also been identified (Gradman, 2009).  
 
The ang II receptor blockers (ARBs) have proven particularly useful in identifying the 
pathophysiological role of ang II in CVDs. These agents specifically block ang II, formed 
from both ACE and non-ACE sources, and do not impede the additional beneficial 
haemodynamic and metabolic actions of other biologically active peptides such as bradykinin 
and angiotensin-(1-7) [Ang-(1-7)] (figure 2.3.). Losartan is the the first orally active, 
selective, and potent nonpeptide ARB (Ferrario, 2006). The ARBs do produce more specific 
blockade of pro-inflammatory mediators than ACE inhibitors (Unger & Stoppelhaar, 2007), 
and reduce the incidence of new-onset type 2 diabetes by approximately 20%–25% (Picard & 
Auwerx, 2002). The ARB, telmisartan, displays a structural resemblance to pioglitazone, a 
thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR-γ) ligand, that is 
used in the treatment of type 2 diabetes (Pershadsingh, 2004). However, not all ARBs are 
capable of activating PPAR-γ (Unger & Stoppelhaar, 2007). 
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Figure 2. 4: Pathways for the formation and degradation of ang-(1-7) in the kidney (Dilauro 
& Burns, 2009). 
 
Several angiotensinases and peptidases are able to metabolize ang II further to form 
biologically active smaller peptides such as ang III, ang IV, and ang 1-7 (Kobori et al., 2007). 
The heptapeptide ang-(1-7) produces its biological effects such as vasodilatation, natriuresis, 
diuresis, and anti-trophic effects by interacting with a non AT1/AT2 receptor. Ang-(1-7) is the 
endogenous ligand for the G-protein-coupled receptor mas, the stimulation of which leads to 
production of NO and prostacyclin (PGI2). Ang-(1-7) (endogenous and exogenous) enhances 
the baroreflex (Diz et al., 2008). Ang-(1-7) may contribute to the antihypertensive effects of 
both ACE-Is and ARBs. By preventing ACE-mediated peptide degradation and increasing 
ang I availability, ACE inhibition elevates ang-(1-7). The ARBs also increase ang-(1-7) by 
increasing the availability of ang I, by blocking the AT1-mediated negative feedback on 
renin, and promoting conversion of ang II to ang-(1-7) via increased ACE2 expression (figure 
2.4) (Ferrario, 2006; Dilauro & Burns, 2009). 
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9.1.4. MULTIPLE ANTAGONISMS OF THE RENIN ANGIOTENSIN 
ALDOSTERONE SYSTEM  
 
Figure 2. 5: The renin angiotensin cascade and the three available approaches towards 
pharmacological inhibition of the production or action of ang II. Direct renin inhibitors (DRI), 
angiotensin-converting enzyme inhibitors (ACEI), and angiotensin (AT) type 1 receptor 
blockers (ARB) (Gradman & Kad, 2008). 
 
Monotherapy with ACE-Is, in doses commonly used in clinical practice, does not always 
result in complete RAAS blockade. Furthermore, there are alternative pathways for 
converting ang I to ang II; such as chymase, cathepsin D and chymotrypsin-like angiotensin 
generating enzyme, in the kidney, heart and blood vessels (figure 2.5). The use of an ACE-I 
reduces the short loop negative feedback of ang II on the JGA, resulting in a reactive increase 
in renin release and, thereby, continued ang I generation (Doulton & Macgregor, 2009). The 
use of aliskiren in combination with other inhibitors of the RAAS prevents the reactive rise in 
ang I and ang II which occurs with ACE-I and ARB combinations (figure 2.5) (Berl, 2009; 
Doulton & Macgregor, 2009). 
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9.1.5. ALDOSTERONE   
Aldosterone is a mineralocorticoid synthesized in the zona glomerulosa of the adrenal gland 
in response to increased ang II, adrenocorticotropin and potassium levels in plasma. It 
regulates electrolyte, fluid balance and BP homoeostasis (Connell & Davies, 2005). It also 
mediates maladaptive tissue remodelling throughout the CV and central nervous system. 
Primary hyperaldosteronism leads to a greater frequency of resistant HTN (a state in which 
the BP remains high despite the use of three antihypertensive agents, one of which is ideally a 
diuretic), as well as CVD and chronic kidney disease (CKD) morbidity and mortality, 
compared with essential HTN (Aoki et al., 2010; Briet & Schiffrin, 2010; De-An et al., 2010; 
Whaley-Connell et al., 2010; Lymperopoulos et al., 2011). Spironolactone and eplerenone 
both antagonise the effects of aldosterone at its receptor (Ferrario, 2006). 
 
9.1.6. THE BRADYKININ SYSTEM 
The BP lowering property of the bradykinin system has been documented for more than 80 
years. Kallikreins are a distinct group of serine proteases that can generate vasoactive kinins. 
The CVS actions of bradykinin, the most important endogenous kinin involved in the 
regulation of arterial BP includes reducing TPR by producing vasodilatation in most areas of 
the circulation, and the regulation of sodium excretion from the kidney. The bradykinin 
system regulates sodium water balance, renal and cardiac haemodynamics, and BP by 
mediating and modulating a) the vasoconstricting RAAS; and b) the vasodilating 
prostaglandin, prostacyclin, adrenomedullin and NO. Reduced activity of the system has been 
reported in various hypertensive situations in both clinical and experimental models of HTN 
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(Lessa et al., 2008; De Leo et al., 2009; Günthner et al., 2009; Sharma, 2009; Bakris, 2010; 
Hanif et al., 2010). 
  
9.2. PERIPHERAL VASCULAR RESISTANCE 
Another method of controlling high BP is by reducing the TPR with drugs, such as prazosin 
and nifedipine (Levick, 2003). The main haemodynamic abnormality in established severe 
HTN is an elevation of TPR with normal CO. However, in mild early HTN, there is a high 
CO with normal TPR often accompanied by an elevated HR. Elevated TPR is usually 
associated with higher plasma noradrenaline levels. Vasoconstrictor α1-adrenergic fibres are 
the dominant nerve supply to most arteries, although some β1-adrenergic and some 
cholinergic vasodilatator nerves may be present.  Sympathetic nerves (acting through the β1-
receptors) and parasympathetic nerves (acting through muscarinic receptors) alter the rate and 
force of contraction of the heart muscle. Sympathetic activation of β1-adrenoceptors also 
stimulates the release of renin into the circulation from the kidneys (Grassi, 2009; Paton & 
Waki, 2009; Weir, 2009).  
 
9.2.1. CALCIUM CHANNEL BLOCKERS  
Calcium channel blockers (CCB) block the entry of calcium ions into VSMCs, thereby, 
reducing the active tone of VSMs and leading to vasodilatation. They include (a) the 
phenylalkylamines (e.g. verapamil), (b) the benzothiazepines (e.g. diltiazem), (c) the 
dihydropyridines (e.g. nifedipine) and (d) the diphenylpiperazine. The agents in groups (a), 
(b), and (c) are used in the management of HTN; while the last group is used in treating 
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neurological disorders such as migraines, neuropathic pain, and dementia. A major feature of 
the long-term action of CCBs is the prevention of the structural changes induced by HTN in 
heart and arteries (Mason, 2002; Godfraind, 2005).  
 
9.2.2. DRUGS THAT ALTER SYMPATHETIC NERVOUS SYSTEM             
FUNCTION  
These agents are able to reduce one or more of the following; venous tone, HR, cardiac 
contractility, CO, and TPR; by interfering with the sympathetic control of the CVS by (a) 
reducing sympathetic outflow from VMC in the brainstem but allowing these centres to retain 
or even increase sensitivity to baroreceptor control, e.g. methyldopa, clonidine, guanabenz, 
and guanfacine, (b) blocking acetylcholine from stimulating the postganglionic autonomic 
neurons, (c) blocking the normal physiologic release of noradrenaline from postganglionic 
sympathetic neurons, e.g. guanethidine and reserpine, (d) selectively blocking the α1 
adrenergic receptors in arterioles and venules, while allowing noradrenaline to exert 
unopposed negative feedback on its own release, consequently, dilating both resistance and 
capacitance vessels, and producing vasodilation as well as venodilation. Salt and water 
retention occurs when these agents are used without diuretics, and are more effective when 
used in combination with β blockers and diuretics, e.g., prazosin, terazosin, doxazosin, (e) 
reducing the BP secondary to reducing CO, and are very useful in lowering BP in mild to 
moderate HTN, and prevent reflex tachycardia associated with treatment with direct 
vasodilators in severe HTN. They prevent catecholamines from binding to β1, β2, and α1 
adrenoceptors. Traditional beta-blockers (eg, atenolol, metoprolol and propranolol) affect 
only the β adrenergic receptors, while carvedilol and labetalol mediate vasodilation through 
blockade of the α1 adrenoceptor. Other drugs like nebivolol may induce vasodilation by 
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stimulating the release of NO (Cruickshank, 2007; Cheng, 2009; Weir, 2009; Benowitz, 
2011; Trevor et al., 2011).  
 
9.3. EXTRACELLULAR FLUID VOLUME 
Diuretics can lower BP up to 10 -15 mmHg by increasing sodium and water excretion in 
urine, thereby, reducing the ECF volume, blood volume and CO; the TPR may, however, 
increase. After six to eight weeks, CO returns to normal while TPR falls.  Sodium may 
increase vascular resistance directly by increasing vessel stiffness and neural activity. These 
drugs are adequate for mild to moderate essential HTN, and induce diuresis by (a) acting on 
specific membrane transport proteins in renal tubular epithelial cells (loop diuretics, 
thiazides, amiloride, and triamterene), (b) exert osmotic effects that prevent water 
reabsorption (mannitol), (c) inhibit enzymes (acetazolamide), or (d) interfere with hormone 
receptors in renal epithelial cells (spironolactone) (Levick, 2003; Katzung, 2004).  
 
9.4. VASCULAR SMOOTH MUSCLE 
Vasodilators can relax the VSMs of arterioles, thereby, reducing TPR. They do not induce 
orthostatic hypotension or sexual dysfunction since the sympathetic reflexes are intact. They 
work best in combination with other antihypertensives to oppose the compensatory CV 
responses to decreased arterial resistance and MAP such as sympathetic activation; and 
comprise of (a) the oral vasodilators (hydralazine and minoxidil, used for long term 
management of HTN); (b) the parenteral vasodilators (nitroprusside, diazoxide, and 
fenoldopam, used in hypertensive emergencies); and (c) the CCBs (discussed above, which 
are used in both situations) (Katzung, 2004). 
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Gradually the pattern of use of antihypertensive agents has changed, from prime use of 
diuretics and β blockers, to preference for the inhibitors of the RAAS as well as the CCBs 
(Opie, 2009).  
 
10. THE RESEARCH PROBLEM 
T. violacea has been observed to reduce BP in normotensive rats by inhibiting the ACE 
(Ramesar et al, 2008) and also in the DSS rats, by decreasing the renal AT1 receptor gene 
(Mackraj et al, 2008). The present study aims to confirm these anti-hypertensive effects and 
furthermore, investigate other mechanisms (beside ACE inhibition and reduction in renal AT1 
receptor gene expression) by which the T. violacea may bring about its hypotensive effect in 
SHR. 
 
11. THE RESEARCH HYPOTHESIS      
In SHR, T. violacea;  
(i) reduces BP and HR 
(ii) inhibits ACE 
(iii) blocks angiotensin II receptors 
(iv) blocks α1 and β1 adrenoceptors 
(v) stimulates cholinergic receptors 
(vi) reduces serum aldosterone levels   
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12. AIMS  
To determine the effect of crude methanol leaf extracts of T. violacea on the BP and HR of 
male SHR. 
To propose mechanisms of action by which T. violacea brings about its effects on the BP and 
HR in SHR. 
To compare the effects of known drugs with that of T. violacea. 
To find out the effect of the plant extract on serum aldosterone levels. 
 
 
13. OBJECTIVES 
1. To investigate if T. violacea decreases BP and HR in the SHR. 
2. To investigate if T. violacea acts by blocking ACE in the SHR. 
3. To investigate if T. violacea acts by blocking angiotensin II receptors in the SHR. 
4. To investigate if T. violacea works by blocking α1 and β1 adrenoceptors in the SHR. 
5. To investigate if T. violacea works by stimulating the cholinergic receptors in the 
SHR. 
6. To investigate if T. violacea works by reducing plasma aldosterone levels. 
7. To compare the effects of T. violacea with that of known antihypertensive drugs. 
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CHAPTER THREE 
METHODS AND MATERIALS 
Chapter 3 describes the different methods employed in the extraction of the plant, the in vivo 
assessment of the crude extract, the analysis of the blood gas, and the radio-immunoassay 
quantification of aldosterone levels in serum. The equipment and chemicals used in the study 
are also listed in this chapter.  
 
1. METHODS USED IN EXTRACTION 
Fresh plants were purchased from the New Plant Nursery, George, Western Cape, SA, in 
August and September, 2008. The plant was identified by the taxonomist at the Department 
of Biodiversity and Conservation Biology of the University of the Western Cape (UWC), 
Bellville, SA; and deposited at the herbarium with voucher numbers 6955 and 6956. The 
remaining leaves were separated from the bulb, and weighed 2.378 kg before they were 
washed with normal water and afterwards, with distilled water, and then dried at 30°C in a 
ventilated oven for 72 hours, before being ground into a fine powder. The soxhlet apparatus 
was used to extract the ground leaves in methanol over a period of 24 hours and the resulting 
extract was filtered through a filter paper to remove small solid particles. The rotavapor was 
used to remove excess solvent in vacuo to afford a thick black paste. The dried black paste 
obtained was placed in a -20 °C freezer before being dried further using a freeze-drier. The 
final dried extract (76.6 g or 3.22% yield) was stored in a brown bottle in a refrigerator at -4 
°C. Fresh MLE was dissolved with drops of DMSO and the required concentration made up 
with 0.9% NS and filtered before being infused into each rat to prevent the formation of 
emboli.  
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1.1. MATERIALS USED IN EXTRACTION  
The equipments used in the extraction process included: a) the Soxhlet apparatus, b) heating 
mantles, c) grinder, d) Rotovapor (Bibbly Sterilin, England), e) freeze-drier (Labconco, 
Missouri), f) 0.45 µm filter papers (Schleicher & Schuell MicroScience). The chemicals used 
were methanol (Sigma-Aldrich, Steinheim, Germany) and b) distilled water 
 
2. THE ANAESTHETIZED SPONTANEOUSLY HYPERTENSIVE RAT 
MODEL 
Healthy male SHR within the weight range of 300 g and 350 g were used for the in vivo study 
of the compound. The animals were weighed and anaesthetized with sodium pentobarbitone 
(40 mg/kg) injected by the intra-peritoneal route. Anaesthetized animals were then transferred 
to a small animal operating table and restrained. A temperature probe was inserted into the 
rectum to monitor the animal’s temperature throughout the experiment. Adjustments to body 
temperature were done by either increasing or decreasing the heating on the small animal 
operating table to keep rectal temperature at 37.3  0.5 oC. A midline incision was made in 
the throat region to access the trachea, and an incision made into the trachea.  A lubricated 
hollow tracheal tube was carefully inserted into the trachea through the incision and secured 
in place with knot. The tracheal tube was cleared of fluids, and an oxygen mask placed over 
the (head and) throat region to facilitate breathing. The external jugular vein was then 
exposed and excess tissue carefully cleaned off it, before it was clamped at the end proximal 
to the heart with a bulldog clamp to prevent blood loss. The exposed section was then filled 
with blood by gently massaging the head, and tied off at the end proximal to the head. An 
incision was made into the vein, and a catheter lubricated with K-Y jelly and filled with a 
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10% heparin solution was carefully inserted into the vein and secured in place. The femoral 
region was afterwards opened and the femoral artery carefully separated from the 
accompanying vein, nerve as well as surrounding tissue. The artery was tied off at the distal 
end and clamped with the bulldog at the proximal end. An incision was made into the artery 
between the tied end and the clamp, and a lubricated catheter filled with a 10% heparin 
solution carefully inserted and secured with knot. The bulldog clamp was then carefully 
removed to allow for blood flow into the catheter.  Incisions were cleaned, covered with 
gauze and kept moist for the duration of the experiment. After surgery, animals were allowed 
a 30 minute recovery period before the commencement of experiments. During the recovery 
period, BP calibrations were done on the Chart 5 software and recording of parameters 
started (Obikeze, 2009). After the 30 minute stabilization period, animals whose BP and HR 
readings were below the expected values for HTN in the SHR (systolic BP (SBP) less than 
150 mmHg and HR below 300 bpm) were excluded from the experiments. SHR normally 
have higher HR rates compared to their normotensive counterparts (Dickhout & Lee, 1998; 
Valenti et al., 2009; Williams, 2010). A syringe pump was used to infuse drugs at a constant 
rate (0.3 ml/min) through the venous cannula. A sufficient recovery period of 30 minutes was 
allowed between individual doses so that the BP and HR can return to baseline values. In the 
experiments in which normotensive animals were used as control for the effect of T. violacea 
on BP and HR, the age of the animals were kept below 5 months, and animals which had BP 
and HR readings that were beyond the normal ranges (SBP 116 mmHg – 145 mmHg; 
diastolic BP 76 mmHg – 97 mmHg; mean arterial BP 103 mmHg – 129 mmHg; and HR 296 
– 388 bpm) were excluded from the experiment (Krinke, 2000).  
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2.1. ANIMALS  
Male spontaneously hypertensive Wistar rats (SHR) aged less than 5 months, were used to 
investigate the BP and/ or HR effects of the crude methanol leaf extract (MLE) of T. 
violacea. The SHR was used in this study as it (i) mimics human HTN remarkably well (ii) 
allows studies in chronic, stable disease, (iii) produces symptoms which are predictable and 
controllable, (iv) satisfied economical, technical and animal welfare considerations, and (v) 
allows measurement of relevant cardiac, biochemical and haemodynamic parameters 
(Doggrell & Brown, 1998; Nakao et al., 2009). Male animals were preferred to female 
animals due to the higher prevalence of HTN in male animals compared to females (Iams & 
Wexler, 1979; Bachmann et al., 1991; Reckelhoff, 2001; Ostadal et al., 2009; Valenti et al., 
2009). Young adult rats (aged < 5 months) were also used as haemodynamic properties such 
as HR, CO, BP and related vascular parameters, have been found to change during the 
lifetime of rats (Roberts & Goldberg, 1976).  To serve as control, some male normotensive 
Wistar rats aged less than 5 months were used (Doggrell & Brown, 1998).  
 
2.2. MATERIALS USED IN THE ANAESTHETIZED HYPERTENSIVE RAT MODEL  
The equipments used includes a) a small animal operating table (BioScience, Cape Town, 
SA), b) syringe pump (Ascor AP22, CA, USA), c) oxygen mask; and d) the BP transducer, 
Power Lab 4/20T unit, Chart 5 for windows software, and BP amplifier were all obtained 
from AD instruments, Bella Vista, Australia.  The drugs and chemicals used include a) 
angiotensin I (ang I), b) angiotensin II (ang II), c) captopril, d) losartan, e) phenylephrine, f) 
prazosin, g) dobutamine, h) propranolol, i) muscarine, and j) atropine. Except when stated 
otherwise, all drugs were sourced from Sigma-Aldrich, Steinheim, Germany. Other 
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drugs/chemicals used include i) sodium pentobarbitone (Kyron Laboratories, Johannesburg, 
SA), ii) heparin (Intramed, Porth Elizabeth, SA), iii) normal saline (NS) (Adcock Ingram, 
SA), iv) dimethylsulfoxide (DMSO) (Merck Chemicals, SA), v) oxygen (Afrox, SA) and vi) 
K-Y jelly (Johnson & Johnson, Midrand, SA).      
 
The doses of the crude extract as well as that of the standard drugs used in this study were 
obtained using doses previously used in literature as a guide for the possible dose ranges that 
will be effective in the SHR. Dilutions below and above the doses used in literature were 
tested to obtain the lowest dose that produced an effect on BP and /or HR, as well as the 
maximum effect, which was not lethal in the SHR used in the study. The animals were 
divided into groups containing 8 rats each. The drugs and their respective doses infused were 
a) crude methanol leaf extract (MLE) of Tulbaghia violacea ( 5- 360 mg/kg), b) ang I (3.125 
- 400 μg/kg, c) ang II) (3.125 - 400 μg/kg), d) captopril (0.03125 - 20 mg/kg), d) 
phenylephrine (0.01 - 5.12 mg/kg), e) dobutamine (0.01 - 0.32 mg/kg), f) propranolol (0.1 - 
12.8 mg/kg), g) muscarine (0.16 -10 µg/kg), and h) atropine (0.02 - 20.48 mg/kg)  
 
The doses of losartan (30 mg/kg) (Wong et al., 1990; 1995; Choi et al., 2009a; Susic et al., 
2009b), and prazosin (1 mg/kg) (Nagai et al., 2003; Dabire, 2004; Antunes et al., 2006; 
Wang et al., 2006; Braga et al., 2008; PintÉRovÁ et al., 2009) were obtained from literature. 
These agents, along with captopril do not permit repetitive dosing in the same animal, i.e., the 
administration of higher or lower doses after the previous dose fails/failed to produce a dose-
dependent response in the same animal. A large number of rats (approximately 50) would 
have been needed for each drug. This observation is supported by the previous work by Nagai 
et al. (2003).  
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2.3. EXPERIMENTAL PROTOCOL 
To reveal the mechanisms through which Tulbaghia violacea produced its effect, the 
following protocols were used to co-infuse the standard drug with the crude MLE of T. 
violacea. 
a) Group I: ang I (3.1 - 100 µg/kg) was co-infused with T. violacea (60 mg/kg) to find 
out if the MLE acts through an inhibitory action on the ACE. For each dose of ang I co-
infused with the MLE; (i) a baseline effect of the compound was first determined and 
compared to the effect of the infusion of the DMSO + NS alone, (ii) ang I (3.1 - 100 µg/kg) 
was infused, (iii) after the BP and HR returned to baseline before (iv) ang I (3.1 - 100 µg/kg) 
was co-infused with T. violacea (60 mg/kg). 
b) Group II: a dose-response experiment (DRE) of ang I (3.1 – 100.0 µg/kg) was  
repeated in 8 rats that were pre-treated with captopril (10 mg/kg) to ascertain that the 
exogenous ang I used in the study is converted to ang II, and this conversion can be blocked 
by a known antagonist of the ACE. 
c) Group III: ang II (3.1 - 50 µg/kg) was co-administered with T. violacea (60 mg/kg) to 
investigate if the MLE act by blocking the ang II receptors. For each dose of ang II co-
infused with the MLE; (i) a baseline effect of the compound was first determined and 
compared to the effect of the infusion of the DMSO + NS alone, (ii) ang II (3.1 - 50 µg/kg) 
was infused, (iii) after the BP and HR returned to baseline before (iv) ang II (3.1 - 50 µg/kg) 
was co-infused with T. violacea (60 mg/kg). 
d) Group IV: a dose-response experiment (DRE) of ang II (3.1 – 50.0 µg/kg) was 
repeated in 8 rats that were pre-treated with losartan (30 mg/kg), to ascertain that the 
exogenous ang II used in the study acts through the ang II receptors, and its action can be 
blocked by a known blocker of the ang II receptors. 
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e) Group V:  ang II (0.39 mg/kg/hr) was infused into 8 animals, followed by the infusion 
of T. violacea (60 mg/kg) SHR, after the BP and HR returned to the values observed prior to 
the infusion of the MLE,  losartan (30 mg/kg) was thereafter, infused into the same animal. 
This protocol was carried out to compare the efficacy of the MLE of T. violacea with that of 
losartan 
f) Group VI: phenylephrine (0.01 – 0.16 mg/kg) was co-administered with T. violacea 
(60 mg/kg) to investigate if the MLE acts via the α1 receptors. For each dose of 
phenylephrine co-infused with the MLE; (i) a baseline effect of the compound was first 
determined and compared to the effect of the infusion of the DMSO + NS alone, (ii) 
phenylephrine (0.01 – 0.16 mg/kg) was then infused, (iii) after the BP and HR returned to 
baseline before (iv) phenylephrine (0.01 – 0.16 mg/kg) was co-infused with T. violacea (60 
mg/kg). 
g) Group VII: the protocol in (f) was repeated in some other rats that were pre-treated 
with prazosin (1 mg/kg) to further investigate a possible contribution of the α1 receptors in 
the effect of the MLE. 
h) Group VIII: dobutamine (0.2 – 10.0 µg/kg) was co-administered with T. violacea (60 
mg/kg) to investigate if the MLE act through the β1 receptors. For each dose of dobutamine 
co-infused with the MLE; (i) a baseline effect of the compound was first determined and 
compared to the effect of the infusion of the DMSO + NS alone, (ii) dobutamine (0.2 – 10.0 
µg/kg) was infused, (iii) after the BP and HR returned to baseline before (iv) dobutamine (0.2 
– 10.0 µg/kg) was co-infused with T. violacea (60 mg/kg). 
i) Group IX: dobutamine (2.3 mg/kg/hr) was infused into 8 animals, followed by the 
infusion of T. violacea (60 mg/kg) SHR, after the BP and HR returned to the values observed 
prior to the infusion of the MLE, propranolol (1.6 mg/kg) was thereafter infused into the 
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same animal. This protocol was carried out to compare the efficacy of the MLE of T. violacea 
with that of propranolol 
j) Group X: T. violacea (30, 60 and 120 mg/kg) was infused into 8 animals, that were 
pre-treated with atropine (5.12 mg/kg) to investigate if the MLE acts through the muscarinic 
receptors. 
k) Group XI: This experiment was carried to compare the effect of muscarine with that 
of the MLE, in animals pre-treated with atropine. 8 animals were pre-treated with atropine 
(5.12 mg/kg), and then T. violacea (60 mg/kg) was infused into the animals. Muscarine (2.5 
µg/kg) was then infused into the same animal, after the BP and HR returned to the level prior 
to the infusion of the MLE. The drugs were infused 20 minutes after atropine infusion (Thán 
et al., 2000; Dimo et al., 2003; Dabire, 2004; Adami et al., 2006; Ajay et al., 2007; D. 
Holopherne et al., 2008; Khwanchuea et al., 2008; Lessa et al., 2008; Rattmann et al., 2008; 
De Menezes et al., 2010).  
The effects of the MLE and the standard drugs on SBP, DBP, MAP and HR were evaluated.  
 
2.4. ARTERIAL BLOOD GAS ANALYSIS 
Arterial blood samples were collected from the arterial cannula at the beginning as well as at 
the end of some experiments, to ascertain that the animals received enough oxygen 
throughout the period of the experiment. The samples were collected into EDTA tubes, and 
kept on ice, before being sent to PathCare Laboratory (PathCare Park, Neels Bothma Street, 
N1 City, Good Wood, Cape Town, SA) for analysis.  
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3. THE EFFECT OF CHRONIC (21 DAYS) ADMINISTRATION OF T. 
VIOLACEA (60 MG/KG), CAPTOPRIL (10 MG/KG) OR THE VEHICLE ON 
BODY WEIGHT, BLOOD PRESSURE, HEART RATE AND PLASMA 
ALDOSTERONE LEVELS 
Animals used in this protocol were put through 14 days of acclimatization to get them used to 
being in the restrainer while the BP and HR recordings are being obtained. The body weight, 
BP and HR of the rats used were measured on the first day of study, before rats were divided 
into three groups of eight animals each. The intraperitoneal injection given to the animals 
during the next 21 days were T. violacea (60 mg/kg), captopril (10 mg/kg) or 0.2 mls of the 
vehicle (DMSO + NS). The BP and HR of the animals were measured using the non-invasive 
tail cuff method during the intervention period; while the invasive measurement was used at 
the end of the study period. Blood was collected from the femoral artery of the SHR after the 
BP and HR values had stabilized. The blood was stored in ethylenediaminetetraacetic acid 
(EDTA) tubes and rapidly spun at 10 000 rpm, in a centrifuge to separate the plasma from the 
blood cells. The plasma obtained was then stored in another set of EDTA tubes and placed in 
a – 40 °C freezer. Plasma collected in EDTA bottles give 15% higher yields compared to that 
kept in heparinized tubes (SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS; Prisant et 
al., 2003). The plasma samples were sent to the Veterinary Hormone Laboratory, Faculty of 
Veterinary Science, Onderstepoort, University of Pretoria, for analysis of plasma aldosterone 
levels. 
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4. STATISTICAL ANALYSIS 
The means ± standard errors of the means of the actual values for SBP, DBP, MAP and HR 
from the experiments are reported. The difference between the mean of the BP and/or HR 
obtained at baseline, or with the vehicle and the maximum response obtained with the 
infusion of T. violacea or the standard drug was calculated. The mean change, the mean of 
the individual percentage changes and the percentage difference (in mean) observed with 
each intervention was calculated and statistically analyzed using the Student’s t test for 
significant difference (p < 0.05). The Microsoft Excel software was used for statistical 
analysis, and the Graph pad prism 5 software was used to illustrate the results as graphs. 
 
5. ETHICAL CONSIDERATIONS 
The animals were allowed free access to food and water before the commencement of the 
experiments. The methodology and ethics adhered to in this study were approved by the 
Ethics Committee of the University of the Western Cape, and the registration number 
obtained was 09/7/35.   
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CHAPTER FOUR 
RESULTS 
The presented results include the effect of time (minutes) on the stability of the blood 
pressure (BP), heart rate (HR) and blood constituents during the continuous infusion of a 
vehicle (normal saline, NS) in the SHR. Also presented in this chapter, are the results 
obtained from the dose-response experiments (DRE) of the methanol leaf extract (MLE) of T. 
violacea (alone) and the standard drugs (alone). The results of the effect of the standard drugs 
co-administered with T. violacea on BP and/or HR in the SHR are also presented here.  
 
1. BASELINE BLOOD PRESSURE AND HEART RATE IN THE 
SPONTANEOUSLY HYPERTENSIVE RATS 
 
Figure 4. 1: Recording of the systolic BP (SBP) and diastolic BP (DBP) in a male SHR. Chart 
scaling 1:1. 
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Figure 4. 2: Recording of the BP of the same animal above. Chart scaling 10:1. 
 
Figure 4. 3: Recording of the BP of the same animal above. Chart scaling 100:1. 
 
This protocol was carried out to ascertain that the SHRs used in this study were indeed 
hypertensive in the absence of any (external) intervention. Figure 4.1 above shows a typical 
BP recording on the Chart 5 graph screen obtained from one of the animals used in the 
present study.  It can be deduced that the anaesthetized SHR used in the above recording was 
hypertensive with an approximate baseline SBP of 260 mmHg and a DBP of 170 mmHg. 
Each 0.01 value seen on the chart at the scaling of 1:1 represents a second. Therefore, by 
counting the number of BP ‘spikes’ in each of such boxes and multiplying this by 60, the 
approximate value of the HR of the animal above can be obtained. Using this equation, the 
HR of the rat above is 360 beats per minute (bpm) which is within the normal range for a 
SHR (figure 4.1). However, it should be noted that the values recorded in this study were 
those obtained by clicking on the ‘Data Pad’ icon at the top of the Chart 5 screen which 
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should be more accurate and eliminate the possibility of human error or/ and bias. It is 
advantageous to compress the recording chart, as this permits sampling of a larger number of 
heart beats (spikes) and thus, a more accurate mean value of BP and HR can be obtained. It 
also makes it easier to appreciate the effect of agents that have appreciable effects on BP 
(figures 4.2 and 4.3).   
 
2. THE STABILITY OF BLOOD PRESSURE AND HEART RATE 
This experiment was performed to ascertain that the BP and HR of the rats used in this study 
were steady. The vehicle (drops of DMSO mixed with NS) was infused at a rate of 0.3 ml/hr 
into anaesthetized healthy male SHRs. The ratio of DMSO to NS used herein, and 
subsequently used as vehicle in experiments requiring the dissolution of a drug in DMSO in 
this study was 3:100. Care was taken to use the least amount of DMSO needed to make a 
solution. After 180 minutes, the maximum duration of the in-vivo experiments, it was 
observed that the SBP, DBP, MAP and HR did not significantly deviate from the baseline 
values at time zero (0); of 197.3 ± 1.5 mmHg, 137.3 ± 1.3 mmHg, 157.3 ± 1.6 mmHg and 
382.4 ± 14.3 bpm respectively; and the vehicle did not have any significant effect on either 
the BP or HR (table 4.1).  
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Table 4. 1: The effect of a mixture of dimethyl sulfoxide and normal saline (0.3 ml/hr) on BP 
and HR in SHR. n=8 
TIME SBP DBP MAP HR 
minutes (mmHg) ± SEM (bpm) ± SEM 
0 197.3 ± 1.5 137.3 ± 1.3 157.3 ± 1.6 382.4 ± 14.3 
20 195.0 ± 5.0 133.0 ± 4.4 153.7 ± 4.5 382.4 ± 8.1 
40 188.0 ± 1.0 126.0 ± 1.0 146.7 ± 0.6 385.1 ± 6.4 
60 195.3 ± 0.3 132.0 ± 3.0 153.1 ± 2.1 382.7 ± 5.4 
80 199.0 ± 7.4 134.3 ± 5.8 155.9 ± 6.3 385.7 ± 7.8 
100 198.3 ± 7.3 137.0 ± 7.0 157.4 ± 7.0 378.4 ± 5.7 
120 199.3 ± 8.1 132.7 ± 8.7 154.9 ± 8.5 379.7 ± 4.1 
140 187.3 ± 1.8 127.3 ± 4.3 147.3 ± 2.8 386.7 ± 8.9 
160 194.3 ± 0.7 125.7 ± 5.6 148.6 ± 3.7 387.3 ± 6.1 
180 191.0 ± 3.2 132.0 ± 2.1 151.7 ± 1.9 384.0 ± 9.3 
 
 
3. EFFECT OF T. VIOLACEA ON BLOOD PRESSURE AND HEART RATE IN 
THE SPONTANEOUSLY HYPERTENSIVE RATS  
 
Figure 4. 4: Effect of T. violacea (90 mg/kg) on BP. Chart scaling 100:1. 
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This experiment was performed to investigate if T. violacea had any effect on the BP and/or 
HR in the SHR. The dose at which 80% of the maximum effect on BP, of the MLE was 
achieved was also sought. The doses of the crude MLE of T. violacea used were 5 mg, 10 
mg, 20 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg/kg. In a dose dependent fashion, T. 
violacea reduced (a) the SBP from 212.8 ± 6.4 mmHg at baseline, to 209.2 ± 6.4 mmHg 
(maximum effect of the lowest dose), and to 128.7 ± 8.3 mmHg (maximum effect of the 
highest dose) (figure 4.5 a; table 4.2); (b) the DBP from 156.1 ± 5.0 mmHg at baseline, to 
152.0 ± 5.0 mmHg (maximum effect of the lowest dose), and to 75.3 ± 5.9 mmHg (maximum 
effect of the highest dose) (figure 4.5 b; table 4.2); (c) the MAP from 175.1 ± 5.3 mmHg at 
baseline, to 171.0 ± 5.3 mmHg (maximum effect of the lowest dose), and to 93.3 ± 6.2 
mmHg (maximum effect of the highest dose) (figure 4.5 c; table 4.2); (d) the HR from 398.8 
± 17.4 bpm at baseline, to 393.5 ± 17.0 bpm (maximum effect of the lowest dose), and to 
316.8 ± 18.4 bpm (maximum effect of the highest dose) (figure 4.5 d; table 4.2). These 
results equate to increasing statistically significant (p < 0.05) reductions at doses above i) 20 
mg/kg (for the SBP), ii) 10 mg/kg (for the DBP), iii) 10 mg/kg (for the MAP) and iv) 60 
mg/kg for the HR (figure 4.5; table 4.2). The absolute reductions in the BP and HR values 
were similar at all doses except at the doses of 30 mg/kg and 60 mg/kg, where the reduction 
in HR recorded was significantly (p < 0.05) less than those of the other parameters (SBP, 
DBP and MAP) (figure 4.5; table 4.2). Doses of T. violacea above 150 mg/kg produced 
further reductions in BP and HR parameters, but were lethal in some animals, and were 
consequently not included.  
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Figure 4. 5: Effect of T. violacea (5 - 150 mg/kg) on SBP (a), DBP (b), MAP (c), and HR (d). 
Values are presented as mean ± SEM. * indicates statistical significance. 
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Table 4. 2: Effect of T. violacea on BP and HR.  
DOSE 
(mg/Kg) 
MEAN SBP 
(mmHg) ± SEM 
MEAN DBP 
(mmHg) ± SEM 
MEAN MAP 
(mmHg) ± SEM 
MEAN HR 
(bpm) ± SEM 
DMSO 212.8 ± 6.4 156.1 ± 5.0 175.1 ± 5.3 398.8 ± 17.4 
5.0 209.2 ± 6.4 152.0 ± 5.0 171.0 ± 5.3 393.5 ± 17.0 
10.0 201.4 ± 7.5 143.9 ± 6.6 * 162.7 ± 6.8 * 381.0 ± 19.8 
20.0 187.3 ± 7.8 * 128.9 ± 6.5 * 148.6 ± 6.8 * 368.5 ± 22.4 
30.0 160.3 ± 6.3 * 99.0 ± 6.1 * 119.5 ± 5.9 * 367.0 ± 20.2 
60.0 139.1 ± 5.4 * 82.4 ± 4.0 * 101.5 ± 4.1 * 348.5 ± 17.2 * 
90.0 136.2 ± 4.3 * 78.9 ± 5.1 * 98.2 ± 4.2 * 325.3 ± 17.6 * 
120.0 133.4 ± 4.6 * 78.4 ± 4.7 * 98.3 ± 4.4 * 323.5 ± 16.3 * 
150.0 128.7 ± 8.3 * 75.3 ± 5.9 * 93.3 ± 6.2 * 316.8 ± 18.4 * 
n=8. * indicates statistical significance.   
 
4. DOES T. VIOLACEA ACT BY INHIBITING THE ANGIOTENSIN I 
CONVERTING ENZYME? 
4.1. Angiotensin I dose response curve 
 
Figure 4. 6: Effect of ang I (12.5 µg/kg) on BP. Chart scaling 100:1. 
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This experiment was performed to obtain a dose response curve (DRC) for ang I, which will 
be used in the ensuing experiment, whose aim was to investigate whether T. violacea 
decreases the BP by inhibiting the angiotenisn I converting enzyme (ACE). In a dose 
dependent fashion ang I (3.1 - 100.0 µg/kg) increased; (a) significantly (p < 0.05) the SBP 
from 181.6 ± 7.2 mmHg at baseline, to 195.9 ± 5.8 mmHg, i.e., by 9.5 ± 2.0% (maximum 
effect of the lowest dose), and to 294.9 ± 9.3 mmHg, i.e., by 58.7 ± 3.3% (maximum effect of 
the highest dose); (b)  the DBP from 138.6 ± 6.9 mmHg at baseline, to 148.9 ± 5.6 mmHg, 
i.e., by 11.9 ± 2.5% (maximum effect of the lowest dose), and to   187.8 ± 7.5 mHg, i.e., by 
41.4 ± 2.6% (maximum effect of the highest dose); and (c) the MAP from 152.9 ± 6.6 mmHg 
at baseline, to 164.6 ± 6.3 mmHg, i.e., by 11.0 ± 2.3% (maximum effect of the lowest dose), 
and to 223.5 ± 7.3 mmHg, i.e., by 48.2 ± 2.4% (maximum effect of the highest dose). The 
increases in DBP and MAP were only significant (p < 0.05) at all doses above the least dose 
(3.1 µg/kg) given (figure 4. 7 a). The infusion of ang I doses above 100.0 µg/kg did not lead 
to any further increase in BP, prior to the lethal dose (s) being achieved. The effect of ang I 
(3.1 – 100.0 µg/kg) on HR was not dose-dependent, as both increases as well decreases were 
observed. Significant (p < 0.05) changes in the HR were only observed at the doses of 25.0 
µg/kg and  50.0 µg/kg at which the HR was increased by 5.7 ± 1.3% (from 387.3 ± 4.5 bpm 
to 404.6 ± 6.3 bpm) and 4.5 ± 1.3% (from 387.3 ± 4.5 bpm to 400.6 ± 7.5 bpm) respectively 
(figure 4. 7 b).  
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Figure 4. 7: Effect of angiotensin I (3.1 – 100.0 µg/kg) on BP (a) and HR (b). Values are 
presented as mean ± SEM. * indicates statistical significance. 
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4.1.2.  Effect of angiotensin I co-infused with T. violacea on the BP and HR 
 
 
 
Figure 4. 8: Effects of ang I (a = 12.5 µg/kg, or b = 100.0 µg/kg); co-infused with T. violacea 
(60 mg/kg) on BP. Chart scaling 100:1. 
 
This protocol was carried out to investigate if T. violacea acts by inhibiting the ACE in the 
SHR. Relative to the respective values at baseline, T. violacea (60 mg/kg) infused alone, 
significantly (p < 0.05) reduced the SBP (from 189.5 ± 5.7 mmHg to 112.0 ± 5.9 mmHg) 
(figure 4.9 a), DBP (from 144.6 ± 6.1 mmHg to 66.3 ± 6.4 mmHg) (figure 4.9 b), MAP (from 
159.5 ± 6.1 mmHg to 81.5 ± 5.9 mmHg) (figure 4. 9 c) and HR (from 365.5 ± 5.7 bpm to 
320.4 ± 10.5 bpm) (figure 4.9 d).  
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The infusion of ang I (3.1 – 100.0 µg/kg) as well as the co-infusion of ang I (3.1 – 100.0 
µg/kg) with T. violacea (60 mg/kg) significantly (p < 0.05) increased the mean of the 
maximum SBP, DBP and MAP values attained when compared to the respective values  at 
baseline (figure 4.9). The only exception was at the lowest dose (3.1µg/kg) of ang I, a dose at 
which the infusion of ang I alone did not produce a significant increase in SBP (figure 4.9 a). 
The infusion of ang I (3.1 – 100.0 µg/kg) alone had variable effect on the HR values when 
compared to the values at baseline; with (a) similar HR values observed at the doses of 3.1 
µg/kg, 6.3 µg/kg and 12.5 µg/kg; (b) significant (p < 0.05) increases in HR values observed 
at the doses of 25 µg/kg and 50 µg/kg; and (c) a significant (p < 0.05) decrease in the HR 
observed at 100 µg/kg. Meanwhile, the co-infusion of ang I (3.1 – 100.0 µg/kg) with T. 
violacea (60 mg/kg) did not produce any significant change in HR, except at the dose of 6.3 
µg/kg, at which there was a significant (p < 0.05) fall in HR (figure 4.9 c). 
 
Consequently the co-infusion of ang I (6.3 – 100.0 µg/kg) with T. violacea (60 mg/kg) 
produced reductions in the final value of SBP, DBP, and MAP obtained when compared to 
the values obtained with the corresponding dose of the ang I (6.3 – 100.0 µg/kg) infused 
alone (figures 4.8 and 4.9). The reductions in (a) the SBP were significant (p < 0.05) at the 
ang I doses of 6.3 µg/kg, 12.5 µg/kg, 25.0 µg/kg and 50.0 µg/kg, and equated to 5.0% (from 
236.7 ± 6.1 mmHg to 225.0 ± 5.3 mmHg), 7.6% (from 251.1 ± 5.6 mmHg to 232.0 ± 7.0 
mmHg), 7.1% (from 270.3 ± 6.3 mmHg to 251.0 ± 8.9 mmHg) and 6.3% (from 280.8 ± 7.4 
mmHg to 263.2 ± 6.5 mmHg) reductions (figure 4.9 a) respectively; (b) the DBP were only 
significant (p < 0.05) at the ang I doses of 6.3 µg/kg (from 179.9 ± 8.3 mmHg to 168.5 ± 5.1 
mmHg; i.e., a 6.3% reduction) and 12.5 µg/kg (189.2 ± 6.4 mmHg to 173.7 ± 7.0 mmHg; i.e., 
a 8.2% reduction) (figure 4.9 b); (c) the MAP were significant (p < 0.05) at the ang I doses of 
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12.5 µg/kg (from 209.8 ± 7.2 mmHg to 192.8 ± 5.6 mmHg; i.e., a 8.1% reduction) and 25.0 
µg/kg (from 222.8 ± 6.0 mmHg to 208.7 ± 7.3 mmHg; i.e., a 6.3% reduction) (figure 4.9 c). 
 
The infusion of ang I alone, as well as the co-infusion of ang I (3.1 – 100.0 µg/kg) with T. 
violacea (60 mg/kg) produced variable effects. Therefore, the co-infusion of ang I with T. 
violacea (60 mg/kg) led to variable changes in the mean HR values obtained when compared 
to the infusion of ang I alone; with (a) similar HR observed at the doses of 3.1 µg/kg, 12.5 
µg/kg and 50.0 µg/kg, (b) significant (p < 0.05) reductions HR values obtained at the doses of 
6.3 µg/kg and 25.0 µg/kg, and (c) a significant (p < 0.05)  increase in HR observed at the 
dose of 100 µg/kg (figure 4.9 d). 
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Figure 4. 9: Effect of ang I (3.1 - 100 µg/kg) co-infused with T. violacea (60 mg/kg) on the 
SBP (a), DBP (b), MAP (c), and HR (d). Values are presented as mean ± SEM. * indicates 
statistical significance. 
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4.1.3. Captopril dose response curve 
 
Figure 4. 10: Effect of captopril (2.5 mg/kg) on BP. Chart scaling 100:1. 
 
Captopril is a ACE inhibitor (Smith & Vane, 2003), and was used here to act as a positive 
control for the possible effect of T. violacea on the ACE. The DRE of captopril was carried 
out to obtain the dose at which 80% of the maximum effect of captopril occurs. In this study, 
captopril did not produce any effect on the BP or HR at doses lower than those displayed 
here, when compared to baseline values. All doses (1.3 – 20 mg/kg) presented here, produced 
significant (p < 0.05) reductions in the BP. A dose dependent reduction in BP was only 
observed between the doses of 1.3 mg/kg to 2.5 mg/kg. Captopril reduced (a) the SBP from 
191.2 ± 4.0 mmHg at baseline, to 167.0 ± 9.4 mmHg, i.e., by 12.6 ± 2.4% (maximum effect 
of the lowest dose), and to 101.8 ± 14.1 mmHg, i.e., by 46.7 ± 6.1% reduction (maximum 
effect of the highest dose); (b) the DBP from 141.9 ± 3.7 mmHg at baseline, to 110.0 ± 10.0 
mmHg, i.e., by 22.5 ± 4.3% (maximum effect of the lowest dose), and to 53.6 ± 8.9 mmHg, 
i.e., by 62.2 ± 5.3% (maximum effect of the highest dose); and (c) the MAP from 1158.4 ± 
3.7  mmHg at baseline, to 129.3 ± 9.7  mmHg, i.e.,  by 18.4 ± 3.5% (maximum effect of the 
lowest dose), and to 69.4 ± 10.7 mmHg, i.e., by 56.2 ± 5.7% (maximum effect of the highest 
dose). Further increases in the dose of captopril did not produce any further reduction in BP, 
before the lethal dose was reached, which was at doses above 20 mg/kg (figure 4.11 a). 
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Captopril only produced a significant (p < 0.05) change in the HR value when compared to 
the value at baseline, at the dose of 2.5 mg/kg; which was a 6.1 ± 2.4% reduction (from 372.2 
± 7.4 bpm to 349.6 ± 10.8 bpm) (figure 4.11 b). 
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Figure 4. 11: Effect of captopril (1.3 – 20 mg/kg) on BP (a) and HR (b). Values are presented 
as mean ± SEM. * indicates statistical significance. 
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4.1.4. Angiotensin I dose response curve in rats pre-treated with captopril 
 
Figure 4. 12: Effect of angiotensin I (100.0 µg/kg) on BP after the pre-treatment with 
captopril (10.0 mg/kg). Chart scaling 100:1 
 
Compared to the hypertensive  effect of ang I observed in the absence of captopril (10 mg/kg) 
(figures 4.6 and 4.7); the hypertensive effect observed with ang I (figures 4.12 and 4.13) after 
the pre-treatment of animals with captopril were significantly (p < 0.05) attenuated; and the 
increases in BP were only significant at doses above 3.1 µg/kg. In a dose dependent fashion, 
ang I (3.1 – 100.0 µg/kg) increased (a) the SBP from 151.8 ± 5.2 mmHg observed with the 
infusion of the vehicle,  to 157.3 ± 7.5 mmHg, i.e.,  by 3.6 ± 1.1% (maximum effect of the 
lowest dose), and to 223.1 ± 5.5 mmHg, i.e., by 47.0 ± 4.2%  (maximum effect of the highest 
dose); (b) the DBP from 94.4 ± 4.6 mmHg observed with the infusion of the vehicle,  to 
102.0 ± 6.2 mmHg, i.e., by 8.1 ± 2.0% (maximum effect of the lowest dose), and to 155.8 ± 
5.5  mmHg, i.e., by 65.0 ± 6.5% (maximum effect of the highest dose); (c) the MAP from 
113.5 ± 4.6  mmHg observed with the infusion of the vehicle,  to 120.3 ±  6.5 mmHg, i.e., by 
6.0 ± 1.6% (maximum effect of the lowest dose), and to 178.1  ± 5.2  mmHg, i.e., by 57.0 ± 
5.2% (maximum effect of the highest dose). After pre-treatment with captopril, dose-
dependent increases in BP, as well as dose-dependent reductions in HR were observed. The 
reduction in the HR were from 363.2 ± 8.0 bpm observed with the infusion of the vehicle, to 
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358.9 ± 9.9 bpm, i.e., by 1.2 ± 0.4% (maximum effect of the lowest dose), and to 334.7 ± 8.3 
bpm, i.e., by 7.8 ± 1.3% (maximum effect of the dose prior to the highest dose) (figure 4.13 
b).  
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Figure 4. 13: Effect of ang I (3.1 – 100.0 µg/kg) on BP (a) and HR (b) after pre-treatment with 
captopril. Values are presented as mean ± SEM. * indicates statistical significance. 
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5. DOES T. VIOLACEA ACT BY BLOCKING THE ANGIOTENSIN II 
RECEPTORS? 
5.1 Angiotensin II dose response curve 
 
Figure 4. 14: Effect of ang II (12.5 µg/kg) on BP. Chart scaling 100:1 
This experiment was performed to obtain DRC for ang II, which will be used in the 
experiment to investigate if the MLE reduces BP by blocking the ang II receptors in-vivo. 
Angiotensin II (ang II) (3.1 – 50.0 µg/kg) produced significant (p <0.05) dose-dependent 
increases in BP (figure 4.15 a), which were not associated with any significant change in HR 
at all doses used (figure 4.15 b). Angiotensin II increased (a) the SBP from 182.6 ± 6.2 
mmHg observed at baseline, to 205.4 ± 6.5 mmHg, i.e.,  by 12.5 ± 6.4% (maximum effect of 
the lowest dose), and to 296.0 ± 12.3  mmHg, i.e., by 62.1 ± 7.7% (maximum effect of the 
highest dose); (b) the DBP from 143.9 ± 5.7 mmHg observed at baseline, to 167.8 ± 3.9  
mmHg, i.e., by 16.6 ± 5.3% (maximum effect of the lowest dose), and to 231.0 ± 8.5 mmHg, 
i.e., by 60.5 ± 7.9% (maximum effect of the highest dose); and (c) the MAP from 156.8 ± 5.1 
mmHg observed at baseline, to 180.3 ± 7.3 mmHg, i.e., by 15.0 ± 6.7% (maximum effect of 
the lowest dose), and to 252.6 ± 9.7 mmHg, i.e., by 61.1 ± 9.2% (maximum effect of the 
highest dose) (figure 4.15 a). No further increases in BP were observed with the infusion of 
ang II doses above 50.0 µg/kg, prior to the lethal dose being achieved. 
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Figure 4. 15: Dose-response graph of the effect of angiotensin II (3.1 – 50.0 µg/kg) on BP (a) 
and HR (b). Values are presented as mean ± SEM. * indicates statistical significance. 
 
5.2. Effect of angiotensin II co-infused with T. violacea on the BP and HR   
 
Figure 4. 16: Effect of ang II (12.5 µg/kg) co-infused with T. violacea (60 mg/kg) on BP in a 
SHR. Chart scaling 100:1 
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This experiment was performed to investigate whether T. violacea mediates its anti-
hypertensive effect by blocking the ang II receptors. T. violacea (60 mg/kg) infused alone 
significantly (p < 0.05) reduced the SBP (from 175.2 ± 5.8 mmHg to 96.2 ± 9.1 mmHg), 
DBP (from 132.4 ± 4.5 mmHg to 51.7 ± 7.4 mmHg), MAP (from 146.7 ± 7.9 mmHg to 66.5 
± 7.8 mmHg) and HR (from 374.2 ± 11.6 bpm to 318.7 ± 13.7 bpm) from the values obtained 
with the infusion of the vehicle alone (figure 4.17).  
 
Generally, the co-infusion of ang II with T. violacea (60 mg/kg) did not produce any 
significant change in the final BP and HR values observed when compared to the values 
obtained with the infusion of ang II alone (figure 4.17). However, significant (p < 0.05) (a) 
increases in the SBP were observed at the doses of 3.1 µg/kg (from 194.8 ± 7.4 mmHg to 
214.4 ± 8.1 mmHg; i.e., a 10.1% increase) and 6.3 µg/kg (from 209.2 ± 10.5 mmHg to 234.1 
± 6.0 mmHg; i.e., a 11.9% increase), (b) decreases in the DBP were seen at the doses of 25.0 
µg/kg (from 194.3 ± 6.3 mmHg to 171.8 ± 7.6 mmHg, i.e., a 11.6% reduction) and 50.0 
µg/kg (from 207.2 ± 16.6 mmHg to 177.6 ± 9.0 mmHg, i.e., a 14.3% reduction), (c) decrease 
was observed in the MAP at the dose of 25.0 µg/kg (from 219.4 ± 7.9 mmHg to 200.7 ± 7.0 
mmHg; i.e., a 8.5% reduction) and (d) increases in the HR at the doses of 25.0 µg/kg (from 
341.4 ± 7.0 bpm to 403.4 ± 15.5 bpm; i.e., a 18.2% increase) and 50.0 µg/kg (from 356.7 ± 
17.4 bpm to 395.0 ± 17.6 bpm; i.e., a 10.7% increase). 
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Figure 4. 17: Effect of ang II (3.1 - 50 µg/kg) co-administered with T. violacea (60 mg/kg) on 
the SBP (a), DBP (b), MAP (c), and HR (d). Values are presented as mean ± SEM. * indicates 
statistical significance. 
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5.3. Effect of losartan (30 mg/kg) on BP and HR 
 
Figure 4. 18: The effect of losartan (30 mg/kg) on BP in a SHR. Chart scaling 100:1 
 
Losartan (30 mg/kg) produced significant (p < 0.05) and sustained decreases in the SBP 
(from 186.8 ± 5.5 mmHg to 128.0 ± 5.6 mmHg; i.e., a 31.5 ± 4.2% reduction), DBP (from 
136.5 ± 8.4 mmHg to 78.8 ± 7.6 mmHg; i.e., a 42.6 ± 5.5% reduction) and MAP (from 153.3 
± 7.1 mmHg to 95.2 ± 6.0 mmHg; i.e., a 38.0 ± 4.3% reduction); which were associated with 
little or no effect on HR, when compared with their respective baseline values (figure 4.19).  
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Figure 4. 19: Effect of losartan (30 mg/kg) on BP (a) and HR (b) in the SHR. Values are 
presented as mean ± SEM.  * indicates statistical significance. 
 
 
5.4. Angiotensin II dose response curve in SHR pre-treated with losartan (30 mg/kg)  
 
Figure 4. 20: Effect of angiotensin II (12.5 µg/kg) on BP after the pre-treatment of a SHR with 
losartan (30 mg/kg) Chart scaling 100:1 
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Losartan (30 mg/kg) was used as positive control to investigate if T. violacea acts via the ang 
II receptors in reducing BP.  After pre-treatment of animals with losartan, the BP responses to 
the infusion of increasing doses of ang II (3.1 – 50.0 µg/kg) were significantly (p < 0.05) 
attenuated (figures 4.20 and 4.21 a) when compared to the values previously obtained in the 
absence of losartan (figures 4.14 and 4.15 a). These increases were only significantly (p < 
0.05) higher than those observed with the infusion of the vehicle (alone) at the doses of 25 
µg/kg and 50 µg/kg at which (a) the SBP was increased by 15.6 ± 3.5% (from 144.3 ± 5.1 
mmHg to 166.7 ± 4.9 mmHg) and 24.7 ± 3.7% (from 144.3 ± 5.1 mmHg to 179.9 ± 9.5 
mmHg) respectively; (b) the DBP  was increased by 20.9 ± 6.6% (from 98.5 ± 4.7 mmHg to 
119.0 ± 4.6 mmHg) and 30.4 ± 7.3% (from 98.5 ± 4.7 mmHg to 128.4 ± 10.9 mmHg) 
respectively; and (c) the MAP was increased by 18.8 ± 5.3% (from 113.6 ± 4.8 mmHg to 
135.0 ± 4.5 mmHg) and 27.7 ± 5.8% (from 113.6 ± 4.8 mmHg to 145.1 ± 10.3 mmHg) 
respectively (figure 4.21 a). The effect of ang II on HR was not significant at any of the doses 
administered in the presence of losartan (figure 4.21 b), a finding that is similar to that 
previously observed in the absence of losartan (figure 4.15 b). 
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Figure 4. 21: Effect of ang II (3.1 – 50.0 µg/kg) on BP (a) and HR (b), after pre-treatment with 
losartan (30 mg/kg). Values are presented as mean ± SEM. * indicates statistical significance. 
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5.5. Experiment comparing the effect of losartan (30 mg/kg) with that of T. violacea (60 
mg/kg) during continuous infusion of ang II (0.39 mg/kg/hr) in the SHR 
 
 
 
Figure 4. 22: Effect of T. violacea (60 mg/kg) (a) and losartan (30 mg/kg) (b) on BP during 
continuous infusion of ang II (0.39 mg/kg/hr) in a SHR. Chart scaling 100:1 
 
The continuous infusion of ang II (0.39 mg/kg/hr) in the SHR significantly (p < 0.05) 
increased the SBP in the animals by about 30 mmHg. The initial baseline readings are not 
shown here. Effort was made to ensure that the new ‘baseline’ was relatively steady for 
proper comparison of the effect of the standard drug (losartan) with that of the test drug (T. 
violacea). During continuous infusion of ang II, T. violacea (60 mg/kg) infusion significantly 
(p < 0.05) reduced the SBP by 32.5 ± 2.1% (from 211.4 ± 3.6 mmHg to 142.6 ± 5.1 mmHg), 
the DBP by 47.2 ± 5.8% (from 160.6 ± 3.2 mmHg to 85.4 ± 10.5 mmHg), the MAP by 41.2 ± 
4.2% (from 177.9 ± 2.7 mmHg to 104.9 ± 8.6 mmHg) and the HR by 18.0 ± 2.0% (from 
380.8 ± 6.3 bpm to 312.2 ± 9.9 bpm) in the SHR. In a similar manner, losartan infusion 
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significantly (p < 0.05) reduced the SBP by 23.2 ± 2.4% (from 213.4 ± 3.4 mmHg to 164.0 ± 
7.0 mmHg), the DBP by 32.1 ± 6.1% (from 156.6 ± 4.2 mmHg to 106.4 ± 9.7 mmHg), the 
MAP by 41.2 ± 4.2% (from 175.1 ± 3.8 mmHg to 125.3 ± 8.5 mmHg) and the HR by 4.2 ± 
1.4% (from 383.0 ± 4.2 bpm to 367.0 ± 6.3 bpm. The reductions in SBP, MAP and HR were 
more significant (p < 0.05) when T. violacea was infused compared to when losartan was 
infused. However, the hypotensive effect of losartan lasted very much longer than that of T. 
violacea (which was momentary) (figures 4.22 and 4.23).  
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Figure 4. 23: Effects on BP (a) and HR (b) of losartan (30 mg/kg) or T. violacea (60 mg/kg) 
during continuous infusion of ang II (0.39 mg/kg/hr) in the SHR. Values are presented as mean 
± SEM. * indicates statistical significance 
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6. DOES T. VIOLACEA ACT BY BLOCKING THE ALPHA I 
ADRENOCEPTORS?  
6.1. Phenylephrine dose response curve 
 
Figure 4. 24: Effect of phenylephrine (0.04 mg/kg) on BP in a SHR. Chart scaling 100:1 
 
This experiment was performed to obtain a phenylephrine dose response curve. 
Phenylephrine, an alpha – 1 (α1) receptor agonist (0.01 – 0.16 mg/kg) produced significant (p 
<0.05) dose-dependent increases in BP, which were associated with dose-dependent 
reductions in HR at all doses when compared to the values at baseline (figure 4.25). 
Phenylephrine increased (a) the SBP from 202.3 ± 4.5 mmHg at baseline, to 226.2 ± 4.8 
mmHg, i.e., by 11.8 ± 2.1% (maximum effect of the lowest dose), and to 345.9 ± 8.1 mmHg, 
i.e., by 71.0 ± 4.1% (maximum effect of the highest dose); (b) the DBP from 158.7 ± 3.7 
mmHg at baseline, to 184.3 ± 4.1 mmHg, i.e., by 16.1 ± 3.5% (maximum effect of the lowest 
dose) and to 240.9 ± 6.6 mmHg, i.e., by 51.8 ± 7.3% (maximum effect of the highest dose); 
and (c) the MAP from 173.2 ± 2.6  mmHg at baseline, to 198.2 ± 5.3 mmHg, i.e., by 14.4 ± 
2.6% (maximum effect of the lowest dose), and to 275.9 ± 7.1 mmHg, i.e., by 59.3 ± 5.2% 
(maximum effect of the highest dose (4.25 a). The associated reductions in HR were from 
403.6 ± 9.0 bpm at baseline, to 401.6 ± 6.7 bpm, i.e., by 0.5 ± 1.5% (maximum effect of the 
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lowest dose), and to 350.7 1 ± 2.9 bpm, i.e., by 13.1 ± 0.6% (maximum effect of the highest 
dose), and were only significant (p < 0.05) at the three highest doses given (figure 4.25 b).  
0.01 0.02 0.04 0.08 0.16
160
180
200
220
240
260
280
300
320
340
360
Dose (mg/kg)

MAP
SBP
DBP









 





NS
(a)
BP
 (m
mH
g)
0.01 0.02 0.04 0.08 0.16
340
360
380
400
Dose (mg/kg)

NS
Phenylephrine


(b)
HR
 (b
pm
)
 
 
 
 
 
Figure 4. 25: Dose-response graph of the effect of phenylephrine (0.01 – 0.16 mg/kg) on BP (a) 
and HR (b). Values are presented as mean ± SEM. * indicates statistical significance. 
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6.2. Effect of phenylephrine (0.01 – 0.16 mg/kg) co-infused with T. violacea (60 mg/kg) 
on BP and HR 
 
Figure 4. 26: Effect of phenylephrine (0.04 mg/kg) co-infused with T. violacea (60 mg/kg) on 
BP in a SHR. Chart scaling 100:1 
 
This protocol was performed to assess if T. violacea reduces BP and HR by blocking the α1 
adrenoceptors. The infusion of T. violacea (60 mg/kg) alone, significantly (p < 0.05) reduced 
the SBP (from 195.0 ± 6.1 mmHg to 116.4 ± 6.3 mmHg), DBP (from 153.0 ± 4.6 mmHg to 
72.2 ± 5.7 mmHg), MAP (from 167.0 ± 4.5 mmHg to 86.9 ± 5.2 mmHg) and HR (from 386.2 
± 11.9 bpm to 332.3 ± 18.4 bpm) when compared with values obtained with the vehicle alone 
(figure 4.27). Phenylephrine (0.01 – 0.16 mg/kg) produced significant (p < 0.05) increases in 
SBP, DBP, MAP; which were associated with dose-dependent decreases in HR when 
compared to the values obtained with the vehicle alone (figure 4.27). The co-infusion of 
phenylephrine (0.02– 0.08 mg/kg) with T. violacea (60 mg/kg) produced significant (p < 
0.05) increases in SBP, DBP and MAP, which were associated with reductions in HR (that 
were not significant) when compared to the values obtained with the vehicle alone. The final 
mean values of the SBP, DBP, MAP and HR obtained with the co-infusion of the 
phenylephrine  with T. violacea were similar to those obtained with the infusion of 
phenylephrine alone at all doses. Significant (p < 0.05) reductions were observed with the co-
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infusion of the standard drug with the MLE at the dose of 0.01 mg/kg (for the DBP and 
MAP) and 0.16 mg/kg (for SBP, DBP and MAP) when compared to the values obtained with 
the infusion of the standard drug alone (figure 4.27). 
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Figure 4. 27: Effect of phenylephrine (0.01 – 0.16 mg/kg) co-infused with T. violacea (60 
mg/kg) on the SBP, DBP, MAP and HR in SHR. Values are presented as mean ± SEM. * 
indicates statistical significance.  
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6.3. Effect of prazosin (1 mg/kg) on the BP and HR 
 
Figure 4. 28: Effect of prazosin (1 mg/kg) on BP in a SHR. Chart scaling 100:1 
 
Prazosin is a specific antagonist of the α1 adrenoceptor (Hui & Qiu, 1996; Dabire, 2004; 
Khwanchuea et al., 2008), and was used as the positive control in assessing the effect of the 
MLE on the α1 adrenoceptors. Prazosin (1 mg/kg) produced significant (p < 0.05) and 
sustained (a) 34.8 ± 2.2% decrease in the SBP (from 183.5 ± 5.1 mmHg to 119.9 ± 5.9 
mmHg), (b) 37.7 ± 2.2% decrease in the DBP (from 141.3 ± 5.7 mmHg to 88.7 ± 6.0  
mmHg), (c) 36.5 ± 2.1% decrease in the MAP (from 155.3 ± 5.2 mmHg to 99.1 ± 5.6 
mmHg), and (d) 5.6 ± 0.9% decrease in HR (from 386.4 ± 4.2 bpm to 364.9 ± 5.3 bpm) 
(figures 4.28 and 4.29).  
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Figure 4. 29: Effect of prazosin (1 mg/kg) on BP (a) and HR (b) in the SHR. Values are 
presented as mean ± SEM.  * indicates statistical significance. 
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6.4. Effect of phenylephrine (0.01 – 0.16 mg/kg) co-infused with T. violacea (60 mg/kg) 
on the BP and HR after pre-treatment of animals with prazosin (1 mg/kg). 
 
 
 
Figure 4. 30: Effect on BP of (a) T. violacea (60 mg/kg) alone, (b) phenylephrine (0.16 mg/kg), 
and (c) phenylephrine (0.16 mg/kg) co-infused with T. violacea (60 mg/kg) in animals pre-
treated with prazosin (1 mg/kg). 
 
This protocol was performed to observe if the pre-treatment of the animals with prazosin 
would alter the response of the rats to the infusion of phenylephrine alone, as well as the co-
infusion of phenylephrine with T. violacea (see section 4.6.2. above). All the increases in BP 
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observed in this protocol were significantly (p < 0.05) less than those observed in the absence 
of prazosin (figure 4.27). The infusion of phenylephrine (0.02 – 0.16 mg/kg) alone, as well as 
the co-infusion of phenylephrine (0.01 – 0.16 mg/kg) with T. violacea (60 mg/kg) produced 
significant (p < 0.05) dose dependent (p < 0.05) increases in the SBP, DBP and MAP when 
compared to the values at the new ‘baseline’ produced by prazosin (1 mg/kg); with each dose 
of the phenylephrine co-infused with T. violacea, having similar final BP values as its 
corresponding dose (of phenylephrine) infused alone. The infusion of the least dose of 
phenylephrine alone, did not produce any increase in BP, therefore the values obtained with 
its co-infusion with T. violacea were significantly (p < 0.05) higher at this dose (figure 4.31). 
The infusion of phenylephrine alone as well as the co-infusion of phenylephrine with T. 
violacea did produce any change in HR, when compared to the ‘baseline’ values, except at 
the dose of 0.08 mg/kg where a significant (p < 0.05) increase in HR was seen with the 
infusion of the standard drug alone, and this was the only dose where the co-infusion of the 
standard drug with the MLE showed a reduction in the final HR value when compared to the 
value obtained with the standard drug alone); and 0.16 mg/kg (where a significant (p < 0.05) 
decrease in HR was seen with the co-infusion of the standard drug with the MLE) (figure 
4.31 d). 
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Figure 4. 31: Effect of phenylephrine (0.01 – 0.16 mg/kg) co-infused with T. violacea on the 
SBP (a), DBP (b), MAP (c), and HR (d) after pre-treatment of animals with prazosin. Values are 
presented as mean ± SEM. * indicates statistical significance.   
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7. DOES T. VIOLACEA ACT BY BLOCKING THE BETA I ADRENOCEPTORS? 
7.1 Dobutamine dose response curve 
 
 
 
 
Figure 4. 32: Effect of dobutamine (10.0 µg/kg) on BP in two SHRs. Chart scaling 100:1 
 
This experiment was carried out to investigate the contribution of the β1 adrenoceptors to the 
reductions in BP and HR observed with the infusion of T. violacea in the rats. As shown in 
the tracings above, the effect of dobutamine (0.2 – 10.0 µg/kg) on BP was not predictable 
(figure 4.32), but partly dose dependent (figure 4.33 a). Dobutamine produced significant (p 
< 0.05) increases in BP at a few doses. Significant (p < 0.05) increases in (a) SBP from the 
baseline value of 190.2 ± 6.2 mmHg, were observed at the doses of 1.3 µg/kg (a 6.5 ± 1.1% 
increase to 202.6 ± 5.8 mmHg), 5.0 µg/kg (a 11.2 ± 1.2% increase to 211.5 ± 5.7 mmHg) and 
10.0 µg/kg ( a 17.3 ± 1.4% increase to 223.2 ± 6.4 mmHg); (b)  DBP from the baseline value 
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of 135.6 ± 7.0 mmHg, was only observed at the dose of 10.0 µg/kg (a 10.9 ± 2.9% increase to 
150.4 ± 6.7 mmHg); and (c) MAP from the baseline value of 153.8 ± 6.4 mmHg, were 
observed at the doses of 5.0 µg/kg (an 8.6 ± 1.7% increase to 167.0 ± 5.4 mmHg) and 10.0 
µg/kg (a 13.5 ± 2.6% increase to 174.6 ± 6.8 mmHg) (figure 4.33 a). Dobutamine increased 
the HR in a dose-dependent manner from 394.0 ± 7.9 bpm at baseline, to 399.5 ± 7.2; i.e., by 
1.4 ± 0.5% (maximum effect of lowest dose), and to 518.4 ± 8.3 bpm, i.e., by 31.6 ± 2.1% 
(maximum effect of highest dose) (figure 4.33 b). 
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Figure 4. 33: Effect of dobutamine (0.2 – 10.0 µg/kg) on BP (a) and HR (b). Values are 
presented as mean ± SEM.  * indicates statistical significance.  
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7.2. Effect of dobutamine (0.2 – 10.0 µg/kg) co-infused with T. violacea (60 mg/kg) on        
the BP and HR in SHR 
 
Figure 4. 34: Effect of dobutamine (10.0 µg/kg) co-infused with T. violacea (60 mg/kg) on BP 
in a SHR. Chart scaling 100:1 
 
Compared to the values obtained with the infusion of the vehicle alone, (a) the infusion of T. 
violacea (60 mg/kg) alone significantly (p < 0.05) reduced the SBP, DBP, MAP and HR, 
without any significant change in pulse pressure (PP) observed (figures 4.34, 4.35); (b) the 
infusion of dobutamine (0.2 – 10.0 µg/kg) alone produced increases in the SBP, DBP, PP, 
MAP and HR, which were only significant (p < 0.05) at (i) the three highest doses (of 2.5 
µg/kg, 5.0 µg/kg, and 10.0 µg/kg) with respect to the SBP, the PP and the MAP; and (ii) all 
doses above 0.3 µg/kg with respect to the HR (figure 4.34); (c). the co-infusion of 
dobutamine with T. violacea produced increases in SBP, DBP, PP, MAP and HR which were 
significant (p < 0.05) at (i) all doses with respect to the SBP, (ii) the doses of 0.2 µg/kg, 0.6 
µg/kg, 1.3 µg/kg and 2.5 µg/kg with respect to the DBP, (iii) the doses of 0.2 µg/kg, 0.6 
µg/kg, 1.3 µg/kg 2.5 µg/kg and 5.0 µg/kg with respect to the MAP, (iv) all doses above 1.3 
µg/kg with respect to the HR (figure 4.35), (v) none of the doses given with respect to the PP 
(result not shown here).  
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Therefore, the final mean values obtained with the co-infusion of dobutamine with T. 
violacea when compared with the values obtained with the corresponding dose of dobutamine 
infused alone were (a) similar at all doses with respect to the SBP except at the doses of 1.3 
µg/kg (at which there was a statistically significant (p < 0.05) increase) and 10.0 µg/kg (at 
which there was a statistically significant (p < 0.05) decrease) (figure 4.35  a); (b) similar at 
the doses of 0.3 µg/kg, 5.0 µg/kg and 10.0 µg/kg with respect to the DBP, but significantly (p 
< 0.05) higher at the doses of 0.2 µg/kg, 0.6 µg/kg, 1.3 µg/kg and 2.5 µg/kg (figure 4.35 b); 
(c) similar at the doses of  0.3 µg/kg, 0.6 µg/kg, 2.5 µg/kg and 5.0 µg/kg with respect to the 
MAP, while (i) significant (p < 0.05) increases were observed at the doses of 0.2 µg/kg and 
1.3 µg/kg, and (ii) a significant (p < 0.05) decrease was observed at the dose of 10.0 µg/kg 
(figure 4.35 c); (d) similar at all doses with respect to the PP, except at the dose of 0.2 µg/kg 
(at which a significant (p < 0.05) reduction was observed) (result not shown here); (e) 
significantly (p < 0.05) lower at all doses with respect to the HR (figure 4.35 d).  
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Figure 4. 35: Effect of dobutamine (0.2 – 10.0 µg/kg) co-infused with T. violacea (60 mg/kg) on 
the SBP (a), DBP (b), MAP (c), and HR (d) in SHR. Values are presented as mean ± SEM. * 
indicates statistical significance.  
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7.3. Propranolol dose response curve 
 
Figure 4. 36: Effect of propranolol (0.08 mg/kg) on BP in a SHR. Chart scaling 100:1 
 
In this study, propranolol was used as a positive control for the possible effect of the MLE on 
the β1 adrenoceptors, although propranolol is a non selective β adrenoceptor blocker which 
acts on both beta 1(β1) and beta 2 (β2) receptors (Dimo et al., 2003; Lin et al., 2007; Weir, 
2009). In a dose-dependent manner, propranolol (0.1 – 3.2 mg/kg) reduced (a) the SBP from 
189.7 ± 3.3 mmHg observed at baseline, to 179.6 ± 4.8 mmHg, i.e., by 1.2 ± 0.6% (maximum 
effect of lowest dose), and to 134.3 ± 7.6 mmHg, i.e., by 29.2 ± 3.5% (maximum effect of 
highest dose); (b) the DBP from 143.6 ± 4.5 mmHg observed at baseline, to 143.0 ± 5.3 
mmHg, i.e., by 0.4 ± 0.8% (maximum effect of lowest dose), and to 90.0 ± 9.5 mmHg, i.e., 
by 37.3 ± 5.9% (maximum effect of highest dose); (c) the MAP from 159.1 ± 3.9 mmHg at 
baseline, to 158.2 ± 4.7 mmHg, i.e., by 0.6 ± 0.7 % (maximum effect of lowest dose), and to 
104.9 ± 8.3 mmHg, i.e., by 34.1 ± 4.7% (maximum effect of highest dose) (figure 4.37 a); 
and (d) the HR from 371.3 ± 8.69 bpm observed at baseline, to 370.6 ± 5.9 bpm; i.e., by 0.2 ± 
0.2% (maximum effect of lowest dose), and to 324.2 ± 11.2 bpm; i.e., by 12.7 ±1.4% 
(maximum effect of highest dose) (figure 4.37 b). Propranolol did not have any significant 
effect on PP (figure 4.36). 
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Figure 4. 37: Dose-response graph of the effect of propranolol (0.1 – 3.2 mg/kg) on BP and 
HR. Values are presented as mean ± SEM.  * indicates statistical significance. 
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7.4. Experiment comparing the effect of T. violacea (60 mg/kg) with that of propranolol 
(1.6 mg/kg), during continuous infusion of dobutamine (2.3 mg/kg/hr) 
 
 
 
 
 
 
Figure 4. 38: Effect of T. violacea (60 mg/kg) (a) or propranolol (1.6 mg/kg) (b) on BP, during 
continuous infusion of dobutamine (2.3 mg/kg/hr) in a SHR. Chart scaling 100:1 
 
The continuous infusion of dobutamine (2.3 mg/kg/hr) in the SHR did not produce a 
significant increase in BP from that at baseline, although the initial baseline readings are not 
shown here. Effort was made to keep the BP and HR due to dobutamine infusion steady for 
proper comparison of the effect of the standard drug with that of the test drug (T. violacea), 
and also to avoid over-stimulating the β1 receptors and consequently, jeopardizing the 
survival of the animal for the duration of the experiment. During continuous infusion of 
dobutamine, T. violacea (60 mg/kg) significantly (p < 0.05) reduced (a) the SBP by 15.9 ± 
3.1% (from 195.1 ± 6.3 mmHg to 165.0 ± 10.8 mmHg); (b) the DBP by 18.4 ± 4.2% (from 
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134.7 ± 8.5 mmHg to 111.4 ± 11.2 mmHg); and (c) the MAP by 15.6 ± 4.1 (from 154.7 ± 7.5 
mmHg to 132.0 ± 11.4 mmHg). T. violacea (60 mg/kg) did not produce any significant 
reduction in HR. Propranolol (1.6 mg/kg) significantly (p < 0.05) reduced (a) the SBP by 
17.3 ± 6.6% (from 199.4 ± 4.1 mmHg to 164.6 ± 12.2 mmHg); (b) the DBP by 18.3 ± 10.7% 
(from 139.0 ± 7.8 mmHg to 109.3 ± 7.8 mmHg); (c) the MAP by 19.3 ± 8.9% (from 159.0 ± 
6.3 mmHg to 125.7 ± 9.5 mmHg); and (d) the HR by 14.8 ± 1.5% (from 423.9 ± 7.3 bpm to 
361.1 ± 8.8 bpm). The observed reductions in SBP, DBP and MAP were similar with both the 
infusion of T. violacea and propranolol, however the reduction in HR produced by 
propranolol was significantly (p < 0.05) greater than that observed with the MLE (figure 
4.39). Neither propranolol nor T. violacea had a significant effect on PP (result not shown 
here).  
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Figure 4. 39: Effects on BP (a) and HR (b) of propranolol (1.6 mg/kg) or  T. violacea (60 
mg/kg) during continuous infusion of dobutamine (2.3 mg/kg/hr) in the SHR. Values are 
presented as mean ± SEM. * indicates statistical significance. 
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8. DOES T. VIOLACEA ACT BY STIMULATING THE MUSCARINIC 
RECEPTORS? 
8.1. Muscarine dose response curve 
 
Figure 4. 40: Effect of muscarine (10.0 µg/kg) on BP in a SHR. Chart scaling 100:1 
 
This experiment was performed to assess the effect of muscarine on BP and HR. In a dose-
dependent fashion, muscarine (0.2 – 10.0 µg/kg) reduced (a) the SBP from 197.9 ± 5.6 
mmHg at baseline, to 180.2 ± 3.8 mmHg, i.e., by 8.9 ± 1.9% (maximum effect of the lowest 
dose), and to 67.1 ± 3.6 mmHg, i.e., 66.1 ± 2.2% (maximum effect of the highest dose); (b) 
the DBP from 136.7 ± 8.2 mmHg at baseline, to 123.3 ± 7.1 mmHg, i.e., by 9.8 ± 2.3% 
(maximum effect of the lowest dose), and to 31.9 ± 6.8 mmHg, i.e., by 76.7 ± 5.4% 
(maximum effect of the highest dose); (c) the MAP from 157.3 ± 7.2 mmHg at baseline, to 
123.3 ± 7.1 mmHg, i.e., by 9.4 ± 2.1% (maximum effect of the lowest dose), and to 44.1 ± 
5.2 mmHg, i.e., by 71.9 ± 3.4% (maximum effect of the highest dose) (figure 4.40 a). 
Muscarine only produced significant (p < 0.05) reductions in HR from 382.6 ± 7.0 bpm at 
baseline, at the last 2 doses of 2.5 µg/kg (a 6.6 ± 0.9% decrease to 357.3 ± 8.3 bpm) and 10 
µg/kg (a 55.6 ± 1.6% decrease to 169.7 ± 6.3 bpm) (figure 4.41 b). 
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Figure 4. 41: Dose-response graph of the effect of muscarine (0.2 – 10.0 µg/kg) on systolic 
pressure (SBP), diastolic pressure (DBP), mean arterial pressure (MAP) and heart rate (HR). 
Values are presented as mean ± SEM.  * indicates statistical significance. 
 
 
8.2. Atropine dose response curve  
 
Figure 4. 42: Effect of atropine (5.12 mg/kg) on BP in a SHR. Chart scaling 100:1 
 
200910 atropine 
B
P
 (
m
m
H
g
) 
80 
100 
120 
140 
160 
180 
34 
Atropine 
(5.12 
mg/kg) 
infusion 
starts 
35  1:14:00 1:18:00 1:22:00 1:26:00 1:30:00 1:34:00 
 atropine infusion ends 
time (hr) 
 
 
 
 
93 
 
In this study the doses lower than those presented here failed to produce any appreciable 
effect on either BP or HR. In literature (Brown & Taylor, 2011; Pappano, 2011), increases in 
BP were reported at doses lower than those presented here. This was not observed in these 
experiments. The doses presented here are the doses at which consistent effects on the BP 
were observed. In a dose-dependent fashion, atropine (0.02 - 20.48 mg/kg) reduced (a) the 
SBP from 188.5 ± 2.7 mmHg at baseline, to 168.8 ± 4.9 mmHg, i.e., by 2.8 ± 0.4% 
(maximum effect of the lowest dose), and to 125.5 ± 5.2 mmHg, i.e., by 33.4 ± 2.3% 
(maximum effect of the highest dose); (b) the DBP from 131.5 ± 4.4 mmHg at baseline, to 
111.8 ± 7.7 mmHg, i.e., by 3.1 ± 1.6% (maximum effect of the lowest dose), and to 60.8 ± 
9.4 mmHg, i.e., by 53.7 ± 6.1% (maximum effect of the highest dose); (c) the MAP from 
150.2 ± 4.0 mmHg at baseline, to 131.0 ± 6.7 mmHg, i.e., by 2.6 ± 1.0% (maximum effect of 
the lowest dose), and to 81.2 ± 8.0 mmHg, i.e., by 46.0 ± 4.1% (maximum effect of the 
highest dose) (figure 4.43 a). The reductions in HR observed with atropine (0.02 – 20.48 
mg/kg) when compared to the value of 373.2 ± 4.5 bpm at baseline, were not dose-dependent 
and significant (p < 0.05) reductions were only observed at the doses of  0.32 mg/kg (a 4.6 ± 
2.7% reduction to 356.2 ± 12.0 bpm),  5.12 mg/kg (a 14.5 ± 2.5%  reduction to 319.1 ± 14.0 
bpm) and 20.48 mg/kg ( a 33.8 ± 2.2% reduction to 246.9 ± 10.3 bpm) (figure 4.43 b).  
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Figure 4. 43: Dose-response graph of the effect of atropine (0.02 – 20.48 mg/kg) on BP and 
HR. Values are presented as mean ± SEM.  * indicates statistical significance. 
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8.3. Effect of T. violacea (30, 60 and 120 mg/kg) on BP and HR, after pre-treatment of 
animals with atropine (5.12 mg/kg) 
 
 
 
 
 
Figure 4. 44: (a) effect of co-infusing T. violacea (60 mg/kg) with atropine (5.12 mg/kg) on BP; 
effect of infusing T. violacea (b = 60 mg/kg, c = 120 mg/kg) on BP, 20 minutes after the pre-
treatment of a SHR with atropine (5.12 mg/kg). Chart scaling 100:1 
 
The effect of simultaneous co-infusion of atropine (5.12 mg/kg) with T. violacea (60 mg/kg) 
was similar to those normally observed with the infusion of T. violacea alone (figure 4.44 a). 
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However, the infusion T. violacea, 20 minutes after pre-treatment of the animals with 
atropine (5.12 mg/kg), led to significant increases in the BP of the rats (figure 4.44 b and c), 
as opposed to the hypotensive effect previously reported with the infusion of T. violacea (5 
mg/kg – 150 mg/kg) (figure 4.4). The dose of atropine (5.12 mg/kg) was the dose at which 
80% of maximum BP effect was observed with increasing dose of atropine in the previous 
experiment. After pre-treatment of rats with atropine, the infusion of T. violacea in a dose-
dependent manner significantly (p < 0.05) increased (a) the SBP from 176.5 ± 4.6 mmHg 
observed with the infusion of the vehicle alone by 17.2 ± 1.3% (to 206.9 ± 6.3 mmHg), 24.9 
± 3.0% (to 220.4 ± 6.2 mmHg) and 33.3 ± 2.2% (to 235.2 ± 5.5 mmHg) at the doses of 30 
mg/kg, 60 mg/kg and 120 mg/kg respectively; (b) the DBP from  128.4 ± 4.6 mmHg 
observed with the vehicle by 11.7 ± 2.0% (to 143.5 ± 7.7 mmHg), 17.5 ± 3.3% ( to 150.9 ± 
6.7 mmHg) and 21.0 ± 2.4% (to 155.4 ± 6.0 mmHg) at the doses of 30 mg/kg, 60 mg/kg and 
120 mg/kg respectively; (c) the PP from 48.1 ± 1.6 mmHg observed with the vehicle by 18.7 
± 1.6% (to 63.4 ± 3.0 mmHg), 43.4 ± 4.8% (to 69.5 ± 2.1 mmHg) and 65.6 ± 4.3% (to 79.8 ± 
1.9 mmHg) at the doses of 30 mg/kg, 60 mg/kg and 120 mg/kg respectively; (d) the MAP 
from  144.4 ± 4.5 mmHg observed with the vehicle by 13.8 ± 1.7% (to 164.4 ± 7.1 mmHg), 
20.4 ± 3.1% (to 173.9 ± 6.5 mmHg) and 19.3 ± 4.3% (to 172.3 ± 8.7 mmHg) at the doses of 
30 mg/kg, 60 mg/kg and 120 mg/kg observed with the infusion of 120 mg/kg respectively. 
The only significant (p < 0.05) change in the HR was the 3.4 ± 1.7% increase (from  384.3 ± 
2.75 bpm to 397.4 ± 5.6  bpm) at the dose of 120 mg/kg of the MLE (figure 4.45).  
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Figure 4. 45: Effect of T. violacea (30 mg/kg, 60 mg/kg and 120 mg/kg) on BP (a) and HR (b), 
after pre-treating SHRs with atropine (5.12 mg/kg). Values are presented as mean ± SEM. * 
indicates statistical significance.  
 
8.4. Experiment comparing the effect of muscarine (2.5 µg/kg) with that of T. violacea 
(60 mg/kg) after pre-treatment of animals with atropine (5.12 mg/kg)  
 
Figure 4. 46: Effect of infusing muscarine (2.5 µg/kg) on BP, 20 minutes after the pre-
treatment of a SHR with atropine (5.12 mg/kg). Chart scaling 100:1 
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After pre-treatment of animals with atropine (5.12 mg/kg), the BP returned back to the initial 
baseline value, which was not the case with the HR (results not shown here). Subsequent 
infusion of muscarine (2.5 µg/kg) did not produce any change in BP and/or HR (as 
previously seen in figures 4.39 and 4.40), i.e., the BP and HR reducing effect of muscarine 
previously reported were nullified (figure 4.46). However, T. violacea (60 mg/kg) still 
produced significant (p < 0.05) 17.2 ± 3.6% increase in the SBP (from 192.1 ± 2.9 mmHg to 
225.7 ± 9.8 mmHg) and 11.0 ± 3.5% increase in the MAP (from 166.0 ± 4.9 mmHg to 184.7 
± 9.9 mmHg). Consequently, the increases in SBP and MAP observed with the infusion of T. 
violacea were significantly (p < 0.05) higher than those observed with muscarine. 
Furthermore, the reductions in DBP and HR previous seen with muscarine (2.5 µg/kg) 
(figures 4.39 and 4.40) and T. violacea (60 mg/kg) (figures 4.4) were obliterated after pre-
treatment of animals with atropine (5.12 mg/kg) (figure 4.47). 
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Figure 4. 47: Effects on BP (a) and HR (b) of muscarine (2.5 µg/kg) or T. violacea (60 mg/kg) 
infused 20 minutes after the pre-treatment of SHRs with atropine (5.12 mg/kg). Values are 
presented as mean ± SEM. * indicates statistical significance. 
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9. EFFECT OF CHRONIC ADMINISTRATION OF T. VIOLACEA, CAPTOPRIL 
OR THE VEHICLE (DMSO + NS) ON BODY WEIGHT, BLOOD PRESSURE, 
HEART RATE, PLASMA LEVELS OF ALDOSTERONE IN SHR 
9.1. Body weight  
Intraperitoneal administration of T. violacea (60 mg/kg/day), captopril (10 mg/kg/day) or the 
vehicle (DMSO + NS) into SHRs, for 21 days did not produce any statistically significant 
change in the mean body weight of any of the rat groups (figure 4.48).  
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Figure 4. 48: Effect of chronic (21 days) intraperitoneal administration of T. violacea (60 
mg/kg/day), captopril (10 mg/kg/day) or the vehicle (DMSO + NS) on the body weight (g) of 
SHR. Values are presented as mean ± SEM. * indicates statistical significance. 
 
9.2. Blood pressure and heart rate  
9.2.1. Non-invasive measurement 
On the 8
th
 day of the study, statistically significant (p < 0.05) reductions in the SBP of  4.1% 
(from 207.2 ± 2.5 mmHg to 198.6 ± 2.2 mmHg), 6.7% from 204.0 ± 3.9 mmHg to 190.3 ± 
3.1 mmHg) and 11.7% (from 213.1 ± 6.2 mmHg to 188.2 ± 5.1 mmHg) were observed in the 
control, T. violacea and captopril groups respectively. On the 15
th
 day, further statistically 
significant (p < 0.05) reductions in SBP of 2.0% (i.e., to 194.6 ± 3.7 mmHg), 3.1% (i.e., to 
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184.4 ± 3.6) and 13.1% (i.e., to 160.2 ± 4.5 mmHg) were observed in the control, T. violacea 
and captopril groups when compared to their respective values on the 8
th
 day (figure 4.49 a). 
There was no significant change in the HR on the 8
th
 day when compared to the respective 
values on the 1
st
 day of study in any of the groups. However, significant (p < 0.05) reductions 
of 1.9% (from 396.5 ± 3.5 mmHg to 389.2 ± 2.3 mmHg) and 4.5% (from 392.1 ± 7.7 mmHg 
to 374.5 ± 4.8 mmHg) were observed in the control and T. violacea groups respectively on 
the 15
th
 day when compared to the mean values observed on the 1
st
 day of study (figure 4.49 
b). The BP and HR were assessed in anaesthetized animals on the last day of study (day 22). 
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Figure 4. 49: Effect of chronic (21 days) intraperitoneal administration of the vehicle (DMSO 
+ NS), T. violacea (60 mg/kg/day) and captopril (10 mg/kg/day) on SBP (mmHg) and HR (bpm). 
Values are presented as mean ± SEM. * indicates statistical significance. 
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9.2.2. Invasive measurement 
On the 22
nd
 day, as compared to the values obtained in the control group, significant (p < 
0.05) reductions in the SBP (from 173.8 ± 5.5 mmHg to  151.3 ± 4.2 mmHg, i.e., by  11.1%), 
DBP (from 130.8 ± 2.3 mmHg to 111.0 ± 7.4 mmHg, i.e., by 10.4%) and MAP (from 145.0 ± 
3.3 mmHg to 124.4 ± 6.3 mmHg, i.e., by 11.2%) were only observed in the captopril (10 
mg/kg) treated group. The 5.5% reduction in HR (from 365.5 ± 6.9 bpm to 350.3 ± 13.6 bpm) 
observed in the captropril treated group when compared to the value obtained in the control 
group of rats was not statistically significant. The reductions in the SBP of 2.1% (from 173.8 
± 5.5 mmHg to 170.1 ± 7.5 mmHg), the DBP of 5.3 (from 130.8 ± 2.3 mmHg to 123.9 ± 7.3 
mmHg) and the MAP of 3.4% (from 145.0 ± 3.3 mmHg to 140.1 ± 6.8 mmHg); which were 
associated with a 1.5% increase in HR (from 365.5 ± 6.9 bpm to 370.9 ± 14.1 bpm) in the T. 
violacea treated animals were not statistically significant when compared to the respective 
values observed in the control group (figure 4.50).  
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Figure 4. 50: Effect of chronic (21 days) intraperitoneal administration of the vehicle (DMSO 
+ NS), T. violacea (60 mg/kg/day) or captopril (10 mg/kg/day) on BP (a) and HR (b) of male 
SHR. Values are presented as mean ± SEM. * indicates statistical significance. 
 
9.3. Plasma aldosterone levels 
Compared to the plasma aldosterone levels in the control group (1319.5 ± 76.7 pg/ml), 
significantly (p < 0.05) lower values where observed in the T. violacea treated animals (740.2 
± 65.0 pg/ml, i.e., by 43.9%), and the captopril treated animal (838.4 ± 77.9 pg/ml), i.e., by 
36.5% (figure 4.51). 
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Figure 4. 51: Effect of chronic (21 days) intraperitoneal administration of the  vehicle (DMSO 
+ NS), T. violacea (60 mg/kg/day) or captopril (10 mg/kg/day) on serum aldosterone levels 
(pg/ml) of male SHR. Values are presented as mean ± SEM. * indicates statistical significance. 
 
10. ANIMALS EXCLUDED FROM THE STUDY 
On completion of the surgical procedures, anaesthetized SHR with SBP less than 150 mmHg 
and HR lower than 300 bpm, after the 30 minutes stabilization period given to each animals 
after the surgical procedure was completed were excluded from the study, and the total 
number of such animals in this study was 17. 
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CHAPTER FIVE 
DISCUSSION AND CONCLUSION 
1. THE STABILITY OF THE BLOOD PRESSURE AND HEART RATE.  
The animals used in the present study had sustained high blood pressure (BP) levels, i.e., 
were hypertensive, with systolic blood pressures (SBP) greater than 150 mmHg in the 
absence of any intervention/treatment (figures 4.1 – 4.3; table 4.1), thus, satisfying the criteria 
in literature used to classify hypertension (HTN) in the spontaneously hypertensive rat (SHR) 
model of human HTN.  The HR of the SHR used in this study was only slightly higher than 
those of the normotensive animals used, and this is also in line with the observations in 
literature (Dickhout & Lee, 1998; Charles River Laboratories International, 2009; Valenti et 
al., 2009; Williams, 2010). The BP and HR of the rats were largely constant during the period 
it took to complete each protocol, a benefit of conducting studies in the anaesthetized rat 
model (Hearse & Sutherland, 2000; Kurtz et al., 2005). Furthermore, the vehicles, normal 
saline and/or dimethyl  sulfoxide used in this study did not have any significant effect on 
either the BP or HR, and have been previously used separately, and together in similar ratios 
by previous researchers (figures 4.1 – 4.3) (Abdelrahman et al., 2004; Lewis et al., 2005; 
Park et al., 2006; Ahn et al., 2007; Ajay et al., 2007; Chan et al., 2007; Tosaka et al., 2007; 
Mackraj et al., 2008; Ramesar et al., 2008; S. Y. Ryu et al., 2008; H. H. Ryu et al., 2011). 
The results obtained from assessing the blood oxygen, carbon (IV) oxide, bicarbonate as well 
as the base excess before and after the experiments were not shown in the results section as 
no significant changes were observed in any of the values.  
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2. EFFECT OF TULBAGHIA VIOLACEA ON BLOOD PRESSURE AND HEART 
RATE IN THE SPONTANEOUSLY HYPERTENSIVE RATS 
T. violacea produced significant (p < 0.05) reduction in the SBP, DBP, MAP and HR in both 
the SHR (figures 4.4 and 4.5; table 4.2) and normotensive Wistar Kyoto (WKY) rats (the 
results obtained in the WKY rats are not shown here, since they were similar to those 
observed in the SHR). At doses above 30 mg/kg, T. violacea generally produced reductions 
in BP that were significantly (p < 0.05) more pronounced in the SHR, while producing 
reduction in HR that were significantly (p < 0.05)  more pronounced in the WKY (results not 
shown here). The greater reduction in BP values seen in the SHR may largely be due to the 
much higher baseline BP values in the SHR (sometimes over 240 mmHg), when compared to 
the WKY (normally less than 140 mmHg). Consequently, an agent that reduces BP can only 
reduce BP by up to 140 mmHg in the WKY, while being able to reduce BP by up to 240 
mmHg in the SHR.  
 
The reduction in SBP and MAP observed in both SHR and WKY with the administration of 
T. violacea in the present study corroborates the findings of Mackraj et al. (2008) and 
Ramesar et al. (2008). Mackraj et al. (2008) reported that intraperitoneal administration of T. 
violacea (50 mg/kg body weight) reduced the SBP by 9.12 ± 0.31% (mean% decrease from 
day 0 to day 14) in the Dahl salt-sensitive (DSS) rat model, while the control group 
experienced an increase of 4.66 ± 0.56% in SBP at the end of the same period. Meanwhile, 
Ramesar et al. (2008) reported that intravenous (60 minutes) continuous co-infusion of T. 
violacea (50 mg/kg) with exogenous ang I (0.1 mg/kg) at a rate of 50 μL/min produced only a 
2.2% increase in maximum mean arterial pressure when compared to the 14.5% increase 
observed with intravenous co-infusion of DMSO with exogenous ang I in WKY rats. The 
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associated reductions in HR (figure 4.5; table 4.2) in the present study, suggests an 
association between the BP and HR in the manner in which the MLE brings about its 
cardiovascular effect in both the SHR and WKY. There is no previous report on the effect of 
T. violacea on HR in literature. The momentary nature of the BP reduction observed in this 
study (figure 4.4) may suggest that the anti-hypertensive constituent(s) of the crude extract 
has a short half-life, and/or the crude extract also contain vasoconstrictory constituent(s) 
which antagonizes the initial hypotensive effect; thereby, returning the BP towards baseline, 
even though the MLE is still being infused into the animal. Another possible explanation 
could be that the baroreflex response to the decrease in BP produced by the MLE is strong 
enough to return the BP towards baseline level while the MLE is still being infused. 
 
3. DOES T. VIOLACEA ACT BY INHIBITING THE ANGIOTENSIN I 
CONVERTING ENZYME? 
The infusion of ang I alone produced significant (p < 0.05) increases in the SBP, DBP and 
MAP; which were associated with variable effects on the HR (figures 4.6 and 4.7). The 
absence of decreases in HR (figure 4.7) must be due to the ability of ang II (produced from 
ang I) to not only constrict blood vessels, but also its ability to blunt the baroreflex (Kobori et 
al., 2007; Carlson & Wyss, 2008). 
 
The MLE of T. violacea was able to reduce the increases in the BP produced by ang I (figures 
4.8 and 4.9), suggesting that T. violacea antagonized the ACE, thereby, preventing the 
conversion of ang I to the potent vasoconstrictor, ang II. T. violacea has been previously 
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reported to have an ACE inhibitory activity in- vitro (Duncan et al., 1999; Mackraj & 
Ramesar, 2007) and in- vivo in WKY rats (Ramesar et al., 2008).  
 
The co-infusion of ang I with T. violacea led to reductions in HR, which were significant at 
two doses of the standard drug co-infused with the MLE. This may suggest that the MLE was 
able to restore the baroreflex (Kobori et al., 2007; Carlson & Wyss, 2008) by reducing the 
amount of ang II produced. This argument is buttressed by the further increase in HR 
observed with the co-infusion of the highest dose of ang I with T. violacea (figure 4.9 d). 
 
The infusion of captopril into the SHR produced significant (p < 0.05) reductions in BP 
which were not dose-dependent, or associated with significant changes in HR, except at the 
dose of 2.5 mg/kg (figures 4.10 and 4.11). It was also impossible to repeat doses of captopril 
in the same animal, as the greatest discernable decrease in BP, was observed with the first 
dose of captopril given to each animal. This may be due to the long half-life of captopril, 
which varies from 2 to 4 hours (Lechleitner et al., 1990; Benowitz, 2011; Saseen & 
Maclaughlin, 2011).   
 
Although, the dose of 2.5 mg/kg of captopril was observed to have produced 80% of the 
maximum reduction in BP observed in this study (figure 4.11), the dose of 10 mg/kg was 
subsequently used in this study to (a) ensure that the activity of enzymes are better inhibited, 
and (b) utilize a dose that has been previously used in a similar study in literature (Mackraj et 
al., 2008; Ramesar et al., 2008).  After pre-treating animals with captopril, the hypertensive 
effect observed with randomly infused doses of ang I (3.1 – 100.0 µg/kg) were  significantly 
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(p < 0.05) attenuated (figures 4.12 and 4.13), when compared to the values observed in the 
absence of captopril (10 mg/kg) (figures 4.6 and 4.7). Reductions in HR, which were 
significant at the highest doses of ang I given, accompanied the attenuated BP effect (figure 
4.13 b), and these are different from the lack of reductions in HR in animals that were not 
pre-treated (figure 4.7 b). This suggests that captopril adequately inhibited the ACE, and the 
subsequent actions of ang II which includes inhibiting the baroreceptor reflex (Smith & Vane, 
2003; Chen et al., 2007; Hoe et al., 2007; Shin et al., 2009; Thaveau et al., 2010).  
 
4. DOES T. VIOLACEA ACT BY BLOCKING THE ANGIOTENSIN II 
RECEPTORS? 
In the present study, the infusion of ang II alone produced significant dose-dependent 
increases in BP, which were not associated with significant reductions in HR, except at the 
two highest doses given (figures 4.14 and 4.15), indicating baroreflex impairment. The 
normal baroreceptor reflex to increases in BP involves decreases in HR and sympathetic 
nervous system activity. Angiotensin II diminishes the sensitivity of this reflex by 
synaptically inhibiting it in the nucleus tractus solitarii, by increasing sympathetic nerve 
activity while decreasing the vagal tone to the heart. It also directly stimulates the 
myocardium, thus, shifting the operating ‘set-point’ for regulation of sympathetic outflow to 
higher BP (Isaacson & Reid, 1990; Kumagai & Reid, 1994; Averill, 2000; Averill & Diz, 
2000; Bader et al., 2001; Balt et al., 2003; Diz et al., 2008; Smith et al., 2008; Hilzendeger et 
al., 2010; Arnold et al., 2011). This may explain the reductions in HR observed with the two 
highest doses of ang II given alone (figure 4.15). Impairment of the baroreflex has been 
previously reported in many experimental models of HTN, and is believed to be preceding 
the onset of HTN (Sanderford & Bishop, 2002; Veerasingham & Raizada, 2003).  
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The co-infusion of ang II (3.1 – 50.0 µg/kg) with T. violacea (60 mg/kg) generally did not 
lead to significant changes in SBP, DBP or MAP, when compared to the values observed in 
the absence of T. violacea (figures 4.16 and 4.17); except for the significant (p < 0.05) 
increases in SBP at the two lowest doses as well as the significant (p < 0.05) reductions in the 
DBP at the two highest doses; suggesting that the MLE may not reduce BP by blocking the 
angiotensin II type 1 (AT1) receptors. The co-infusion of the standard drug with the MLE 
produced further increases in HR, which were significant (p < 0.05) at the two highest doses 
given (figure 4.17 d) when compared to the values obtained with the standard drug in the 
absence of the MLE (figure 4.15 b), suggesting that the crude extract may contain substances 
which may have cardio-excitatory potential, in the presence of ang II. Mackraj et al. (2008) 
previously observed that chronic T. violacea administration reduced systemic arterial BP in 
the DSS rat by decreasing renal AT1 receptor gene expression and hence, modulating sodium 
and water homeostasis. A possible explanation for the apparent difference in the result 
obtained in this study and that of Mackraj et al. (2008) may be that T. violacea could inhibit 
the expression of new AT1 receptor genes without blocking the function of receptors already 
present as suggested by the results of this study. 
 
As a positive control for the action of the MLE on the (AT1) receptor, a DRC of ang II (3.1 – 
50.0 µg/kg) was conducted in rats pre-treated with losartan, a known ang II receptor blocker. 
The dose of 30 mg/kg (Wong et al., 1990, 1995; Choi et al., 2009a; Susic et al., 2009b) was 
used as the lengthy half-life of losartan, which is about 2 hrs, and that of its terminal 
metabolites which is between 6 and 9 hrs (Lankford et al., 1997; Gainer et al., 1998; Warner 
et al., 1999; Ripley & Hirsch, 2010) means that the conduction of a separate DRC for 
losartan in this study, would have required over 50 rats. The use of such a large number of 
animals for a protocol that is not crucial towards achieving the aims of this study is 
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discouraged by the Ethical clearance obtained for the study. Losartan produced significant (p 
< 0.05) and sustained decreases in the BP when compared to the baseline values with little or 
no effect on the heart rate (figures 4.18 and 4.19). 
 
The observed increases in BP, after the pre-treatment of animals with losartan (figures 4.20 
and 4.21), were significantly (p < 0.05) less than those previously observed in the absence of 
losartan (figures 4.14 and 4.15). The lack of any significant change in HR after pre-treatment 
with losartan was similar to the results previously obtained in the absence of losartan in the 
same study; suggesting that baroreflex was not restored even though the BP effect of ang II  
was attenuated (Averill & Diz, 2000; Veerasingham & Raizada, 2003).  
 
In the experiment to compare the effect of the MLE (60 mg/kg) with that of losartan during 
continuous infusion of ang II, the reductions in the SBP, MAP and HR observed with the 
infusion of the MLE were more significant (p < 0.05) (figure 4.22 a, and 4.23) when 
compared to the corresponding values obtained with losartan (30 mg/kg) (figure 4.22 b., and 
4.23). The equally significant (p < 0.05) reductions in BP values obtained with the standard 
drug lasted much longer, when compared to that obtained with T. violacea (which was 
momentary). T. violacea was therefore, infused before losartan in each animal to allow for 
comparison of BP and HR effect in same animals. This result furthermore suggests that the 
MLE may not act via the AT1 receptors, since the BP profile and magnitude seen in the 
presence of ang II (figures 4.22 and 4.23) were similar to those seen in absence of the agonist 
(ang II) (figure 4.4 and 4.5).  
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5. DOES T. VIOLACEA ACT BY BLOCKING THE ALPHA I 
ADRENOCEPTORS?  
Phenelyephrine is a potent selective α1 adrenergic receptor agonist in arterioles and venules. 
The α1 adrenergic receptors mediate the vasoconstrictory actions of catecholamines, 
especially noradrenaline, thereby, increasing BP when stimulated which is accompanied by a 
baroreflex mediated bradycardia (Katzung, 2004). The infusion of phenylephrine (0.01 – 0.16 
mg/kg) produced dose-dependent increases in the mean values of the SBP, DBP and MAP, 
which were associated with dose-dependent reductions in HR (figures 4.24 and 4.25); i.e., the 
normal baroreflex response to increasing BP (Fazio et al., 2001; Fletcher et al., 2002; 
Veerasingham & Raizada, 2003; Ward & Abdel-Rahman, 2006).  
 
The mean values of the SBP, DBP, MAP and HR attained when phenylephrine (0.01 – 0.16 
mg/kg) was co-infused with T. violacea (60 mg/kg) (figures 4.26 and 4.27), were similar to 
the values obtained with the infusion of the standard drug alone (figures 4.24 and 4.25). The 
results obtained from this protocol suggest that T. violacea may not have any appreciable 
effect on the α1 adrenergic receptors. Although the infusion of phenylephrine alone produced 
significant (p < 0.05) reduction in HR when compared to the values obtained with the vehicle 
alone, the co-infusion of phenylephrine with T. violacea did not produce significant reduction 
in HR, when compared to the values obtained with the vehicle alone (figure 4.25 d). The 
effect on HR obtained with the co-infusion of the MLE with phenylephrine is similar to that 
observed with the co-infusion of ang II with the MLE (figure 4.17 d), and suggests that the 
crude MLE contains some substances that may blunt the normal baroreflex response to 
phenyelphrine. 
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The experiment involving the co-infusion of phenylephrine was repeated, in rats pre-treated 
with prazosin, to investigate if prazosin (a α1 adrenergic receptor antagonist) will give 
answers to questions that were not answered above. The dose of prazosin (1 mg/kg) used in 
this study, has been previously used by other researchers (Nagai et al., 2003; Dabire, 2004; 
Antunes et al., 2006; Wang et al., 2006; Braga et al., 2008; PintÉRovÁ et al., 2009; Wong et 
al., 2011) to block the α1 adrenergic receptors. Its half-life of approximately 3 hours 
(Biaggioni & Robertson, 2011) made it impossible to carry out a DRE. Prazosin (1 mg/kg) 
lead to prolonged statisitical significant (p < 0.05) reduction in SBP, DBP, MAP and HR in 
the SHR (figures 4.28 and 4.29).  
 
Apart from the significantly (p < 0.05) reduced maximum BP responses observed with both 
the infusion of phenylephrine alone as well as the co-infusion of phenylephrine with the MLE 
(figure 4.30) when compared to those seen in the absence of prazosin (figure 4.28 and 4.29), 
the pre-treatment of animals with prazosin in this study did not lead to any different pattern in 
the BP and/or HR effect observed with the standard drug alone, or when co-infused with the 
MLE (figures 30 and 31). This may further suggest that the α1 adrenergic receptors are not 
involved in the anti-hypertensive effect of the MLE. On HR, the co-infusion of the MLE with 
the standard drug produced reductions in the HR, which was significant (p < 0.05) at the dose 
of 0.08 mg/kg when compared to the infusion of the standard drug alone, in the protocol that 
involved the pre-treatment of animals with prazosin (figure 4.31d), as opposed to the lack of 
any change in HR in the protocol that did not involve the pre-treatment of the animals with 
prazosin (figure 4.22d). This may suggest that the presence of prazosin might have blocked 
the constituents of the MLE which might have blunted the baroreflex in figure 4.22d. 
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6. DOES T. VIOLACEA ACT BY BLOCKING THE BETA I ADRENOCEPTORS? 
Although, dobutamine (0.2 – 10.0 µg/kg) led to dose-dependent increases in HR, which were 
significant (p < 0.05) at all doses greater than the two lowest doses, its effect on SBP, DBP, 
PP and MAP were not necessarily dose-dependent even though significant (p < 0.05) 
increases were observed at the highest doses with these parameters (figures 4.32 and 4.33). 
The result obtained in this DRE, agrees to a large extent with what is in literature, wherein 
dobutamine has been reported to have positive inotropic and chronotropic effects on the 
heart, with its effect on BP being variable (Romson et al., 1999; Rang et al., 2000; Brunton et 
al., 2007; Fang & Rocco, 2011; Maclaren et al., 2011). Dobutamine is a racemic mixture, 
having equal amounts of left- and right- enantiomers of a chiral molecule that stimulates β1 
and β2 adrenergic receptors. The (–) enantiomer is an agonist for α adrenergic receptors, 
while the (+) enantiomer is a very weak partial agonist. In humans, the cardiac effects of 
dobutamine predominates, as the vasoconstrictory effects that might have been mediated by 
its action on α adrenergic receptors are neutralized by its vasodilatory actions via the β2 
adrenergic receptors. At low doses, the inotropic effect is greater than the chronotropic effect, 
and is associated with modest decrease in peripheral vascular resistance. In animals, 
administration of dobutamine at rates lower than 20 µg/kg/minute, has been previously 
reported to produce increased inotropism, modest chronotropism, and virtually no change in 
BP (Fang & Rocco, 2011; Maclaren et al., 2011). The rate of infusion of 2.3 mg/kg/hr, used 
in this study was greater than 20 µg/kg/minute, and may explain the pronounced 
chronotropism associated with the modest inotropism (figure 4. 33). Although both subtypes 
of the β receptor present in the heart are excitatory and their stimulation leads to an increase 
in cardiac output, the β1 receptors are the primary adrenergic receptors in the heart (Freeman 
et al., 2006; Cruickshank, 2007; McCorry, 2007).  
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The typical BP profile previously seen in this study for the MLE (figure 4.4) was also seen 
with the co-infusion of the MLE with the standard drug (figure 4.34). Since, the MLE was 
used as an antagonist in the present study, it was the difference between the resultant BP and 
HR effect observed when co-infusing dobutamine (the standard drug) with the MLE, and the 
resultant BP and HR effect of the standard drug alone that was used as a yardstick of how 
potent the effect of the MLE was on the particular mechanism under review. Co-infusing 
dobutamine (0.2 – 10.0 µg/kg) with the MLE produced significant (p < 0.05) reductions in 
the HR values when compared to the values obtained with the infusion of the standard drug 
alone (figure 4.35 d). The co-infusion of dobutamine (0.2 – 10.0 µg/kg) with T. violacea (60 
mg/kg) led to further increases in BP when compared to the values obtained with the infusion 
of the dobutamine alone. These increases were observed to be statistically significant (p < 
0.05) at most doses with respect to the DBP, but only at a dose with respect to the SBP, and 
at two doses with respect to the MAP (figure 4.35). Consequently, there were reductions in 
the PP at virtually all but one dose, which were however, not statistically significant (results 
not shown here). The results obtained suggest that the MLE has significant effect on both the 
HR and cardiac contractility (based on the reduction in the PP seen when dobutamine was co-
infused with T. violacea), when compared to that observed when dobutamine was infused 
alone. This result strongly suggests that the MLE has an inhibitory action on the β1 
adrenoceptor, which may partly explain the previously observed bradycardia produced by the 
infusion of the MLE alone in the SHR (figure 4.5 d), and may explain the resultant 
hypotension (figures 4.4 and 4.5). The product of the TPR and the CO gives one the value of 
the arterial BP (Levine, 1997; Levick, 2003). The DBP represents the lowest value to which 
BP falls in the arteries before the next systolic ejection, and is influenced by the HR and the 
total peripheral resistance (TPR, which is the combined resistance to blood flow in the 
arterioles). The faster heart beats, the less likely the heart muscle are able to sufficiently relax 
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prior to the next systole, therefore, the DBP will rise (Bell, 2008). There is no previous report 
on the effect of T. violacea on DBP (figures 4.4 and 4.5 b). The further increase in DBP 
observed when dobutamine was co-infused with the MLE as compared to when dobutamine 
was infused alone (figure 4.34 b) throws up an interesting question. The answer may be that 
the reduction in DBP which the infusion of the MLE  alone produces (figure 4.5 b), might not 
only have been obliterated by the presence of dobutamine, but that some other constituents in 
the crude extract itself is responsible for the further rise in the DBP observed.  
 
In a related experiment, propranolol was used as a positive control used to compare the effect 
of the MLE on the effect of β1 adrenoceptors. Propranolol is a non selective β adrenoceptor 
blocker, with actions on both the β1 and β2 receptors (Dimo et al., 2003; Lin et al., 2007; 
Weir, 2009). In a dose-dependent manner, propranolol (0.1 – 3.2 mg/kg) reduced the SBP, 
DBP, MAP and HR; but had no effect on the PP (figures 4.36 and 4.37).  
 
During continuous infusion of dobutamine, T. violacea (60 mg/kg) significantly (p < 0.05) 
reduced the SBP, DBP and MAP, but did not produce a significant reduction in HR. 
Propranolol which was infused at the dose which gave 80% of the maximum reduction in BP 
in the DRE (1.6 mg/kg) (figure 4.37) on the other hand; significantly (p < 0.05) reduced the 
SBP, DBP, MAP and HR. Neither propranolol nor T. violacea had a significant effect on the 
PP (figures 4.38 and 4.39). This result furthermore buttresses the argument that the MLE may 
act through the β1 adrenoceptors in the SHR. Agents that inhibit these receptor are very 
useful for lowering BP in mild to moderate HTN, since their stimulation leads to increased in 
HR, CO, and ultimately BP (Katzung, 2004; Cheng, 2009; Weir, 2009).  
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7. DOES T. VIOLACEA ACT BY STIMULATING THE MUSCARINIC 
RECEPTORS? 
Muscarine chloride was used as a positive control for the possible effect of the MLE on the 
muscarinic receptors. Muscarine (0.2 – 10.0 µg/kg) significantly (p < 0.05) reduced the SBP, 
DBP, MAP in a dose dependent manner when compared to values at baseline.  These 
reductions in BP were only associated with reduction in HR at the two highest doses (figures 
4.40 and 4.41).  
 
In literature, muscarine (a parasympathomimetic agent) has been reported be have activity 
similar to that of acetyl choline, although being more potent. Previous reports in literature 
alludes to the fact that muscarine reduces BP, while atropine (a parasympatholytic agent) has 
been reported in literature to have various effects on BP; from increases (Bartholow, 1908; 
Fraser, 1957; Wess et al., 1987), to no effect in WKY rats and SHR (Lazartigues et al., 1999; 
Mestivier et al., 2001), and to immediate and dose-dependent reductions, at the doses of 5-50 
mg/kg given intravenously in conscious unanaesthetized WKY rats and hypertensive rats 
(SHR, and Sprague-Dawley rats made hypertensive by subcutaneous implantation of 
deoxycorticosterone acetate) (Abraham et al., 1981a, 1981b; Cantor et al., 1983). 
Furthermore, Abraham and co-workers (1981a) observed that i) the hypertensive rats showed 
greater responsiveness to the hypotensive action of atropine, even though the plasma 
concentration of atropine was similar in all groups of rats,  ii) the pre-treatment of animals 
with phentolamine, a non-selective α – adrenergic antagonist, abolished the hypotensive 
action of atropine, iii) atropine blocked the pressor effect of phenylephrine in all the animals, 
and the dose-response curve was shifted to the right to a similar degree in all animals (both 
 
 
 
 
117 
 
normotensive and hypertensive), iv) the reduction in BP were associated with increases in 
HR.  
 
In the present study, the infusion of atropine doses lower than 0.02 mg/kg did not produce 
any significant change in BP or HR, as opposed to the increases in BP and HR mentioned in 
some literature (Bartholow, 1908; Fraser, 1957; Wess et al., 1987). In the study conducted by 
Lazartigues et al. (1999), increases in HR were observed in the WKY, but not in the SHR. 
Meanwhile, Muntzel et al. (1997) observed that atropine (200 µg/kg) increased HR, but did 
not affect BP in SHR. In literature, the net cardiovascular effects of atropine in patients with 
normal hemodynamics have been reported to be mild: increases in HR may occur, but there is 
little effect on BP; but the cardiovascular effects of exogenous direct-acting muscarinic 
agonists are easily prevented (Brown & Taylor, 2011; Pappano, 2011). Therefore, the results 
obtained in the present study; i.e., dose-dependent significant reductions in BP observed with 
the infusion of atropine (0.02 - 20.48 mg/kg) which were associated with reductions in HR at 
highest doses when compared with the respective values at baseline (figures 4.42 and 4.43); 
corroborates the results obtained by Abraham et al., (1981a; 1981b) and Cantor et al.,  (1983) 
who reported reduction in BP with atropine infusion, but disagrees with Abraham et al., 
(1981a) with respect to the effect on HR. The lack of tachycardia, in this study, with the 
infusion of atropine in the SHRs used in this study has been previously suggested to be 
possibly due to a depressed parasympathetic nervous activity in hypertensives (van Zwieten 
et al., 1995), although some other investigators (Abraham et al., 1981a; Lazartigues et al., 
1999) opined that it may be due to a lack of vagal tone in free moving conscious animals as 
opposed to anaesthetized animals.  
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In the experiments to observe the effect of simultaneously co-infusing atropine (5.12 mg/kg) 
with T. violacea (30, mg/kg, 60 and 120 mg/kg) (figure 4.5), the results obtained did not 
show the usual BP and/or HR profile seen with the infusion of T. violacea at these doses. The 
prominent BP profile and magnitude was that of atropine (figure 4.44 a). Infusion of agonists 
was done 20 minutes after infusing atropine in most studies in which atropine was used to 
block the muscarinic receptors (Muntzel et al., 1997; Dimo et al., 2003; Delphine 
Holopherne et al., 2008; Khwanchuea et al., 2008; Lessa et al., 2008; Liu et al., 2008; 
Rattmann et al., 2008; Shirasaka et al., 2009; De Menezes et al., 2010).  
 
Consequently, this protocol was repeated, but this time with the agonist infused at least 20 
minutes after pre-treating the animals with atropine. The BP of the animals returned towards 
baseline, but the HR stayed down after treatment with atropine (5.12 mg/kg) (results not 
shown here). The infusion of the MLE (30 mg, 60 mg and 120 mg/kg), led to significant (p < 
0.05) dose-dependent increases in BP (i.e., the SBP, DBP, PP and MAP) of the rats (figures 
4.44 b, 4.44 c and 4.45), as opposed to the dose dependent reduction previously reported with 
the infusion of the MLE alone (5 – 150 mg/kg) (figures 4.4 and 4.5) suggesting that it takes 
atropine some time to adequately block the muscarinic receptors, which must have been the 
reason why previous researchers allowed some time before the infusion of agonists after 
infusing atropine. The only significant (p < 0.05) change in HR was the 3.4 ± 1.7% increase 
observed with the infusion of the dose of 120 mg/kg (figure 4.45). This result strongly 
suggests that the MLE indeed acts through the muscarinic receptors.  
 
After the pre-treatment of the animals with atropine, the effect of muscarine (2.5 µg/kg) on 
BP and HR were nullified (figures 4.46 and 4.47). However, the infusion of T. violacea (60 
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mg/kg) produced significant (p < 0.05) increases in SBP and MAP respectively (figure 4.44 b 
and 4.47). Consequently, the increases in SBP and MAP observed with the infusion of T. 
violacea were significantly (p < 0.05) higher than those observed with muscarine after pre-
treatment of animals with atropine. The HR reducing effect previously observed with the 
infusion of the MLE prior to the treatment of the same animals with atropine was abolished 
after atropine pre-treatment (figure 4.47). It can be inferred from this experiment, that both 
muscarine and T. violacea produce bradycardia, and the consequent reduction in BP by 
actions on the muscarinic receptors in the heart. The increase in BP observed with the 
infusion of the MLE after atropine pre-treatment suggests that the crude extract may also 
contain pressor agents, whose actions may become prominent when one of the mechanisms 
via which the MLE brings about its hypotensive effect is blocked. 
 
8. EFFECT OF CHRONIC (21 DAYS) INTRAPERITONEAL 
ADMINISTRATION OF THE VEHICLE (DMSO + NS), T. VIOLACEA OR 
CAPTOPRIL ON THE BODY WEIGHT, BLOOD PRESSURE AND PLASMA 
ALDOSTERONE LEVEL  
8.1. Body weight  
The administration of T. violacea (60 mg/kg/day), captopril (10 mg/kg/day) or the vehicle 
(DMSO + NS) intraperitoneally for 21 days, did not produce any statistically significant 
change in the mean body weight of any of the groups of SHR (figure 4.48). 
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8.2. Blood pressure and heart rate  
8.2.1. Non-invasive blood pressure and heart rate measurement 
The mean values of the SBP obtained in all the groups of animals used, were significantly (p 
< 0.05) lower after seven days of treatment, when compared to the values obtained on the 
first day of the study; despite a prior 14 day period of acclimatizing the animals to the setup 
used for the tail-cuff measurement. Furthermore, statistically significant (p < 0.05) reductions 
in SBP were observed in the control, T. violacea and captopril groups respectively on day 15 
when compared to the values obtained on day 8 of the study. The observed reductions were 
greatest in the captopril group, and least in the control group of animals. On the final day of 
the experiment (day 22), the BP and HR were assessed in anaesthetized animals (figure 4.49).  
The observed reductions in BP may be partly due to the animals having more time to become 
better acclimatized to the glass restrainer used to limit their movement during tail-cuff 
measurements, as the days passed by. The intra-peritoneal treatment of animals did not 
produce statistically significant changes in HR after the first week of treatment in any of the 
groups. However, significant (p < 0.05) reductions were observed in the control and T. 
violacea groups respectively on the 15
th
 day when compared to the mean values observed on 
the 1
st
 day of study (figure 4.93). The reductions in HR in the T. violacea - treated and - 
captopril treated rats may also be partly due the animals becoming better accustomed to the 
small space, being more relaxed, and consequently, reducing sympathetic nervous system 
activation, which normally would increase HR and BP, as part of the ‘fight’, ‘fright’ or 
‘flight’ response (Kurtz et al., 2005; Freeman et al., 2006; Fox et al., 2007; Hainsworth et al., 
2007; McCorry, 2007; Reil & Bohm, 2007; Craven, 2008).  
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In a review by Kurtz et al. (2005), the authors were of the opinion that the indirect methods 
used in experimental animals share some of the advantages of their use in humans. These 
includes the fact that they do not require surgery, can be used to obtain repeated 
measurements of SBP in conscious animals during studies of short or long duration, require 
less expensive equipment than some direct methods (e.g., telemetry) and can also be less 
expensive to operate, can be used to screen for systolic HTN or substantial differences in SBP 
among large numbers of animals. They also share the same disadvantages of indirect office 
methods of BP measurement widely used in clinical and epidemiological studies that form 
the scientific basis for current clinical practices in HTN. The disadvantages includes the fact 
that they only measure BP in a very small sample of cardiac cycles, they impose significant 
thermal and restraint stress that disturbs multiple aspects of the cardiovascular system such as 
BP, HR and stress hormones, despite the fact that they are non-invasive and investigators try 
their best to train and acclimatize animals to undergo the procedures. Furthermore, the 
accuracy of these methods in animals, particularly the tail-cuff methods, is open to question 
despite the presence of several published studies purporting to validate cuff methods since 
most of the studies were based on faulty analytic techniques involving correlations between 
cuff measurements of BP and direct measurements of BP simultaneously or subsequently 
obtained with arterial catheters in the same animal; instead of using more appropriate 
techniques such as agreement analysis. Finally, these methods are not well suited to 
measuring diastolic pressure. 
 
8.2.2. Invasive measurement blood pressure and heart rate measurement  
Significant (p < 0.05) reductions in the mean values of the SBP, DBP and MAP were 
observed in the captopril (10 mg/kg) treated group, but was not observed in the T. violacea 
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(60 mg/kg) treated group, when compared to the values obtained in the control group. The 
starting SBP (obtained via the tail-cuff transducer) was not statistically different between the 
groups. On HR, there was no statistically significant difference in HR between the groups at 
the end of the experimental period (figure 4.50). This suggests that chronic, 21 - day 
administration of T. violacea (60 mg/kg/day) may not reduce BP or HR in the SHR. This is 
contrary to the previous work of Mackraj et al. (2008) in DSS rats. The results may also 
buttress the observation that the BP and HR effect of the MLE of T. violacea in the acute 
experiments performed in this study were momentary. On the other hand, chronic treatment 
of animals with captopril produced significant reduction in BP, but not in HR. This 
observation is in line with reports in literature (Lechleitner et al., 1990; Smith & Vane, 2003; 
Hu et al., 2007; Havranek, 2008; Mackraj et al., 2008; Zicha et al., 2008; Jovanovic et al., 
2009; Montenegro et al., 2009; Shin et al., 2009).  
  
8.3. Plasma aldosterone levels 
The mean concentration of aldosterone found in the serum of the animals treated with T. 
violacea (60 mg/kg) and captopril (10 mg/kg) after 21 days were significantly (p < 0.05) 
lower, when compared to the mean concentration of aldosterone observed in the control 
group (which were treated with a mixture of DMSO and NS). There was no statistically 
significant difference between the mean concentration of aldosterone observed in the T. 
violacea treated group and that observed in the captopril treated group (figure 4.51). The 
results obtained in the protocol are in agreement with the previous work of Mackraj et al. 
(2008) who observed that T. violacea (50 mg/kg/day) decreased aldosterone secretion in DSS 
rats. Aldosterone regulates electrolyte, fluid balance and BP homoeostasis (Connell & 
Davies, 2005). It also mediates maladaptive tissue remodelling throughout the CVS and 
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central nervous system (CNS), thereby, worsening the HTN (Nistala et al., 2009; Zannad et 
al., 2009; Aoki et al., 2010; Briet & Schiffrin, 2010; De-An et al., 2010; Whaley-Connell et 
al., 2010; Lymperopoulos et al., 2011). Therefore, a reduction in its plasma levels is 
advantageous to the animal. 
 
9. LIMITATION OF THE STUDY 
The scope of this study was limited due to lack of funds and access to some equipment which 
would have enabled the researcher to (a) investigate more mechanisms via which the MLE 
may mediate its anti-hypertensive effect, such as the calcium channels, the alpha 2 adrenergic 
receptors and the possible effect of the MLE on diuresis; (b) isolate and identify the different 
constituents of the crude extract and possibly link each constituent to its own individual BP 
and/or HR effect; and (c) quantify the amount of the different constituent in the extract, and 
the amount in plasma after administration into animals.  
 
10. CONCLUSION 
At the end of the study, all the objectives of the study were achieved. The crude methanol 
leaf extract of Tulbaghia violacea was observed to reduce BP and HR in the male SHR. The 
BP and HR reducing effect of the MLE may involve a) the inhibition of the ACE, b) the 
inhibition of the β1 adrenoceptors, c) the stimulation of the muscarinic receptors and d) a 
reduction in the level of aldosterone in plasma. The results also suggest that the MLE may 
not act through the angiotensin II receptors or the α1 adrenergic receptors.  
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11. RECOMMENDATIONS 
Tulbaghia violacea may be useful as an antihypertensive agent in humans, although further 
studies are required to ascertain its safety and optimal dose for such an application. Such 
studies would include, in addition to those mentioned under the limitations, isolating and 
removing constituents that may negate the potency of the anti-hypertensive constituent(s). It 
will also be crucial to investigate the effect of temperature on the active constituent(s), as 
well as the first pass metabolism, the bioavailability when taken orally, the rate of 
metabolism in the body, the distribution, the half life, toxicity and also the route(s) of 
elimination from the body of its constituents. Finally, an assessment into its interaction with 
other herbs, drugs or food in both experimental animals and in clinical trials would be 
required.  
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